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Epilepsy has been previously attributed to either increased excitation or decreased 
inhibition. With this closed frame of mind, modern medicine has been unable to develop 
a permanent treatment against the mechanisms of epilepsy. In order to treat patients with 
intractable seizures, especially those caused by developmental malformations, it is 
essential to understand the entirety of mechanisms that could possibly play a role in the 
abnormal cortical function. 
One such developmental malformation is known as polymicrogyria. 
Epileptogenesis occurs in an area laterally adjacent to this malformation known as the 
paramicrogyral region (PMR). Past studies have narrowed down the potential cause of 
this increased network excitation to a certain type of inhibitory interneuron, the 
somatostatin (SS) interneuron. Additionally, previous studies have shown an increase in 
the mGlu5 receptor on this interneurons in the PMR region only and not in control tissue, 
meaning that targeting these receptors as treatment will not affect normal functioning 
tissue. These results lead to our hypothesis: blockade of the mGluRs will decrease the 
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activity of SS interneurons and thereby prevent the generation of epileptiform activity 
and increased SS output in malformed cortex. 
Utilizing the freeze-lesion model for microgyria in transgenic mice expressing 
Channelrhodopsin optogenetic channels in SS interneurons, we assessed the contribution 
of these SS interneurons in four different animal groups: control or PMR treated with 
either Gabapentin, a current AED (antiepileptic drug), or MTEP, an mGlu5 receptor 
antagonist. We tested the effects of these two drugs on SS interneuron output to 
determine whether they decrease the over activation in the PMR that has been previously 
studied. The following study revealed no correlation between Gabapentin-treated animals 
and a decrease in epileptiform activity. Additionally, no significant difference was seen 
between the MTEP-treated groups in the protocols that were measured.  
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Chapter 1 
Introduction to Epilepsy, Interneurons, Optogenetics, mGluRs, and Possible 
Treatments 
Polymicrogyria (PMG) causes intractable epilepsy, or epilepsy not 
permanently treatable with medication. In order to properly treat intractable seizures, 
one must understand the underlying mechanisms to target. My project focuses on a 
specific receptor, the mGlu5 receptor, as the key in reducing the epileptiform activity 
seen in our freeze-lesion mice that mimic the hyperexcitablilty and histopathology of 
PMG. This project will aid in the search for a specific treatment for intractable 
seizures as opposed to patients having to result to surgery or a continuous rotating 
drug regimen.  
1.1 Epilepsy – general characteristics 
Epilepsy is a very common disorder that affects around 50 million people 
worldwide or 1-2% of the world’s population (WHO, Epilepsy et al. 2005, Varvel, 
Jiang et al. 2014) It has known to be recorded as “the falling disease” as early as 1060 
BC (Varvel, Jiang et al. 2014). In addition, seizures were thought to be the work of 
demons rather than a neurological condition (Varvel, Jiang et al. 2014). In 400 BC, 
Hippocrates was one of the first people to characterize epilepsy as a disorder of the 
brain, but he was not taken seriously. It was not until the early 1900s the first 
antiepileptic drug (AED) was introduced (Varvel, Jiang et al. 2014). Today, it is 
characterized as a chronic neurological disorder with characteristic seizures, or 
abnormal electrical discharges, that can cause changes in emotional and motor activity 
(Fisher and Saul 1997, Fisher, Arzimanoglou et al. 2014). Epilepsy can also cause 
cellular and molecular changes in between seizure activity (Elger 2005). A seizure is 
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characterized as a synchronous over-activation of one or many synaptic pathways 
(Varvel, Jiang et al. 2014). A consistently lowered threshold of one of these pathways 
may produce epilepsy (Varvel, Jiang et al. 2014). Usually, this uncontrolled electrical 
activity is the cause of too little inhibition or an increase in excitation within the 
cortical network (Davies 1995).  
As discussed by Fisher et al (2014), these seizures either involve specific 
systems of the brain, as in the case of partial seizures, or they can be in a restricted 
area and eventually spread, leading to the involvement of multiple cortical and 
subcortical subunits. An epileptic seizure must have the presence or signs of 
symptoms related to excess neuronal activity, or synchronous activity in the brain as 
demonstrated on electroencephalogram or EEG (Fisher, Arzimanoglou et al. 2014).  
Treatment with AEDs or surgery is at least partially effective in approximately 
2/3 of epilepsy patients (Fisher and Saul 1997). When AEDs are ineffective, not 
possible, or not desired, surgery is the last resort. For AEDs with known mechanisms, 
they target ion channels and postsynaptic receptors to enhance the brain’s ability to 
limit the spread of seizures (Alexander & Godwin, 2006;  Fisher & Saul, 1997). AEDs 
have three different modes of action, they either facilitate GABA transmission through 
multiple mechanisms, they can block voltage gated ion channels which reduces 
excitatory transmission, or they have an unknown/other mode of action (Davies 1995). 
All AEDs treat epilepsy after it is diagnosed, but there are no successful strategies for 
prevention of epilepsy for those at risk (Varvel, Jiang et al. 2014).  
In more than 50% of surgery cases, however, seizures are not eliminated 
completely or they are not even significantly reduced (Palmini, Gambardella et al. 
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1994, Olivier, Andermann et al. 1996). If the seizure has no focal region, or a specific 
area where the seizure originates, then surgery is not an option (Fisher and Saul 1997). 
Ben-Ari stated that understanding and treating seizures caused by developmental 
malformations requires knowledge of cortical networks and cellular mechanisms in 
order to determine the mechanisms that are absent or enhanced. With this knowledge, 
it is possible to understand the underlying mechanisms of the hyperexcitability that are 
seen (Ben Ari 2006).  
Even though some patients are treated with AEDs, 40% of patients have 
seizures that are drug resistant or intractable (Fisher and Saul 1997, Alexander and 
Godwin 2006). The reasons for this intractability are not fully known, but 
approximately 25% of the intractable seizures are caused by malformations of cortical 
development (MCDs), according to Leventer (2008). Classification of MCDs is based 
on the developmental steps of cell proliferation, neuronal migration, and cortical 
organization (Barkovich, Guerrini et al. 2012). These classifications span three 
different groups. Group I constitutes malformations secondary to abnormal neuronal 
and glial proliferation or apoptosis. Group II includes malformations that are 
secondary to abnormal neuronal migration. Finally, Group III contains all the 
malformations secondary to abnormal migrational and post migrational development, 
as the process of cortical organization begins before the termination of neuronal 
migration. Lastly, there are still MCDs that are not classified into groups (Kuzniecky 
2015). Of the 25% of intractable seizures attributed to MCDs, 50% of those are 
diagnosed in children (Leventer, Guerrini et al. 2008). In addition to the high 
prevalence in children, as a whole, approximately 75% of patients diagnosed with a 
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MCD will have epilepsy (Leventer, Guerrini et al. 2008). Thus there is a strong 
connection between these errors in development and cortical hyperexcitability.  
Epilepsy associated with MCDs comes about as a result of the abnormal 
presence or absence of neurons or by the faulty positioning of cortical neurons 
(Leventer, Guerrini et al. 2008, Varvel, Jiang et al. 2014). This misplacement or 
absence can result in an imbalance between the excitatory and inhibitory neuronal 
systems which would normally control this epileptiform activity and prevent these 
spontaneous events from occurring (Leventer, Guerrini et al. 2008). In addition, 
malformations associated with errors in development during the formation of the 
cortical plate have an effect on maturation (Squier and Jansen 2010). Developmental 
malformations are therefore the focus of our epilepsy studies because the biology 
underlying the transition of a normal brain to a brain with epilepsy must differ from 
the biology driving seizures in the epileptic brain (Varvel, Jiang et al. 2014).  
1.2 Malformations – Polymicrogyria 
Developmental malformations are more common than previously realized in 
the past, due to the recent advancements in technology such as magnetic resonance 
imaging or MRI. In fact some malformations, particularly PMG, in some cases, 
require the highest current resolution of MRI (at 7T) in order to be identified (De 
Ciantis, Barkovich et al. 2015).  
One such malformation is known as PMG. PMG is a developmental 
malformation that is present when there are multiple small convolutions on the surface 
of the brain (Kuzniecky 2015). PMG is often associated with type II lissencephaly, or 
“smooth brain”  where there is an absence of normal convolutions (Stouffer, Golden et 
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al. 2015). The distribution of PMG greatly varies from diffuse, symmetrical, bilateral, 
asymmetrical or unilateral (Kuzniecky 2015). With the small convolutions come 
underlying laminar abnormalities. Takano discusses PMG is also one of the most 
common MCDs and has different types, unlayered and 4-layered. We focus on the 4-
layered type. In four-layered PMG, the cortex consists of a molecular layer (1st layer) 
and two neuronal layers underneath (Takano 2011). In between the two neuronal 
layers is an intermediate layer that contains few cells and many fibers (Takano 2011).  
It has been previously reported that approximately 85% of patients diagnosed 
with polymicrogyria have seizure disorders (Leventer, Guerrini et al. 2008). As 
mentioned in Leventer et al. (2008), PMG is also a very common additional 
component with other disorders such as chromosomal deletion syndromes, metabolic 
disorders, and multiple congenital anomaly syndromes. Additionally, PMG , unlike 
other MCDs has non-genetic causes that are recognized (Stouffer, Golden et al. 2015). 
The incidence of epilepsy with PMG is very high (Kuzniecky, Andermann et al. 
1993); the susceptibility of seizures most often peaks during brain growth and 
synaptogenesis during childhood in humans, suggesting that the immature brain is the 
focus for the initiation of the epilepsy (Rakhade and Jensen 2009, Takano 2011). The 
seizures associated with PMG tend to be intractable in about 50% of the cases of 
patients, and also tend to show up in childhood (Leventer, Guerrini et al. 2008). This is 
important because seizures can be caused by different factors depending on the age of 
a person (Fisher and Saul 1997). The young brain is different from the adult brain in 
many ways; the young brain is not a smaller adult brain. We cannot get the 
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information we need from adult brains in order to elucidate the underlying 
mechanisms of developmental epilepsy (Ben Ari 2006).  
In our lab, we use the freeze-lesion (FL) model due to its ability to accurately 
replicate the histopathology and hyperexcitability of the microgyria associated with 
seizures. We specifically look for mechanisms in development because we want to 
ultimately identify the one(s) that produce the onset of this hyperexcitability.  
Freeze lesion model of microgyria  
PMG has been modeled by a number of insults to the neonatal cortex, 
including direct ibotenic acid injection, stabbing punctures, and most commonly, a 
neonatal transcranial FL.  In the normal developing brain, the cortical layers form in 
an inside-out progression, with the bottom layers forming first and the upper layers 
following.  The model used for experiments described in this dissertation is the 
neonatal FL, performed on postnatal day (P) 1 in mouse. Lesions are done on P1, as 
opposed to P0, because lesions at P1 are more likely to cause the chronic 
hyperexcitability (Jacobs, Hwang et al. 1999). The lesion produces a focal loss of 
neurons within the cortical plate at the time of the lesion. At P1 in mouse, this is some 
of layer IV, and all of layers V and VI.  The superficial layer neurons will migrate into 
the cortical plate on subsequent days.  For this model, mice are anesthetized and a 
frozen probe is placed onto the skull overlying somatosensory cortex for a few 
seconds, creating a focal loss of the neurons present in the cortical plate at that 
developmental age (Jacobs and Prince 2005) (Figure A). Thus, this FL process 
mimics a fetal stroke or direct injury resulting in focal loss of neurons. In addition, this 
FL model shows epileptiform activity consistently and is therefore a useful model for 
9 
 
study of the underlying mechanisms of epileptogenesis associated with polymicrogyria 
(Jacobs, Hwang et al. 1999).  
It has been shown that these FL animals have intrinsic hyperexcitability in the 
area adjacent to the lesion. The cortex adjacent to the microgyrus, from which the 
epileptiform activity is most easily evoked is known as the paramicrogyral region or 
PMR. The cellular changes that cause this increased excitation seen in this model are 
unknown, however, the knowledge of these mechanisms will help provide special 
Figure A. Freeze lesion model of microgyria. 
A) Freeze probe diagram, modified from 
Humphreys, Rosen et al. (1991). Probe was 
placed in dry ice to cool methyl butane. B) 
Although previous studies in rat utilized a 
unilateral lesion, for these studies bilateral 
lesions over somatosensory cortex were made 
in mice. C) Probe placement results in focal 
death of cells present in the cortical plate (deep 
layers). D) Over the next 5-7 days normal 
processes remove these cells. E) As a result of 
lost cells a sulcus forms in the normally 
lissencephalic rodent cortex. F) Normal 
migration of superficial layer cells into the 
cortex continues after the lesion. G) Example of 
a Nissl-stained coronal section through 
somatosensory cortex containing the induced 
microgyrus with abnormal lamination and the 
abrupt transition (gray dashed outline) to 
normally laminated 6-layered cortex. This 
example is from a rat. Figures C-G by KM 
Jacobs. 
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targets for therapeutic treatments (Andresen, Hampton et al. 2014). Though the 
mechanisms are unknown, field epileptiform activity has been evoked in the PMR, 
laterally adjacent to this malformation. When connections from the PMR region are 
severed from the microgyrus, the hyperexcitability seen in the PMR region persists 
(Jacobs and Prince 2005). Afferents avoid the microgyrus and instead, relocate to the 
PMR (Rosen, Burstein et al. 2000) (Figure B); this is what leads to increased 
excitatory connectivity in this area (Jacobs, Kharazia et al. 1999, Jacobs and Prince 
2005). Increased excitatory afferents must be selective to certain neurons or other 
components of the circuit in order to overcome the inhibition as with increased 
excitation among pyramidal neurons (Jacobs, Hwang et al. 1999). Is it just excitatory 
afferents causing this hyperexcitability?  
Network hyperexcitability was originally identified with field potential 
recordings in ex vivo slices. Nemes, et al. discussed how pro-epileptic lesions are a 
predisposing factor for the development of chronic epilepsy if triggered by an event 
such as ischemia or a seizure. The presence of hyperexcitability increases a patient’s 
Figure B. Thalamocortical excitatory 
afferents avoid the malformed region 
and project instead to the PMR. In the 
cartoon at the top, the normal focal 
projections can been seen. In the lower 
cartoon depicting the malformed cortex, 
the thalamic afferents that should have 
gone to the malformed area instead find 
the normal layer IV in the adjacent 
(abnormal) region. This creates 
additional excitatory afferents in this 
PMR region. This has been 
demonstrated both anatomically and 
functionally.  Figure by KM Jacobs. 
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chance of developing epilepsy. This is why stopping the hyperexcitability before 
seizures occur is key. While the network epileptiform activity begins abruptly and is 
severe at P12, the functional increase in excitatory activity to layer V pyramidal 
neurons begins on P9.  Thus some other mechanism likely contributes to the initiation 
of the epileptiform activity. This led us to look at inhibitory interneurons as the cause.  
In the PMR region, there are more glutamatergic synapses to layer V 
pyramidal neurons and interneurons (Jacobs & Prince, 2005). This increased 
glutamatergic signaling onto certain subtypes of interneurons is important and could 
affect the excitability of the PMR region (Takano 2011). In the PMR, others from our 
lab have previously shown that layer V pyramidal neurons receive an increase in these 
excitatory connections. The increase in excitatory synapses to excitatory neurons 
occurs at P10, yet we do not see epileptiform field potentials until P12 (Figure C). 
This suggests that there are likely other abnormalities involved in initiating the 
epileptiform activity.  
Figure C. Timing of 
onset of epileptiform 
activity. Activity was 
recorded as field 
potentials from ex vivo 
rat slices. Survival age 
is postnatal day. Note 
that before P12 (purple 
arrow) only normal 
short latency events 
were evoked. Figure 
modified (colorized) 
from Jacobs, Hwang et 
al. (1999). 
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Previous recordings from inhibitory cells showed that inhibitory cells of the 
PMR receive nearly three times the excitation that controls have. What is the cause of 
this excitation? The early susceptibility seen that does not coincide with the increased 
excitation onto pyramidal neurons may be caused by inhibitory neuron changes or 
changes with their connectivity (George and Jacobs 2006, George and Jacobs 2011, 
Bell and Jacobs 2014). In addition, since the onset is delayed, this is an important 
period of latency to study in order to determine the mechanisms of epilepsy, especially 
since seizures alter many processes such as physiological processes that can worsen 
hyperexcitability (Bell and Jacobs 2014).  
There are a few known mechanisms that can contribute to epileptogenesis and 
increased hyperexcitability in the FL model. There are thalamocortical afferents that 
should have projected to malformed region that instead project to the PMR that could 
contribute but not initiate the hyperexcitability. In addition, there are increased AMPA 
and NMDA receptors, and decreased GABA receptors. There is increased excitatory 
input to layer V pyramidal neurons which is an important contributor. Lastly, there are 
GABAergic neurons decreased in number.  This could be an important contributor to 
network hyperexcitability.  After the FL, neurons migrate from the cortical plate and 
form a bridge-like structure. This structure maintains an early Cl- homeostatic 
environment which causes GABA to be depolarizing, promoting the formation of this 
disorganized network and also promoting the abnormal migration of neurons and 
could affect the hyperexcitability seen in the PMR (Shimizu-Okabe et al., 2007). This 
depolarizing effect of GABA is essential in order for neurons and interneurons to 
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migrate (Wang, Kumada et al. 2012). The effect of GABA can affect not only effect 
excitatory neurons, but can also effect inhibitory neurons.  
1.3 Inhibitory interneuron subtypes 
In the cortex, 70-80% of the neocortical neurons are excitatory pyramidal cells, 
the other 20-30% are inhibitory interneurons (White 1989). There are many types of 
GABAergic interneurons that are distinguishable by their morphology/axonal 
arborization because certain interneurons are specialized at targeting different domains 
of neurons, different cortical columns, or even different layers of a column (Markram, 
Toledo-Rodriguez et al. 2004). Inhibitory neurons have certain characteristics that 
make them distinguishable from pyramidal neurons such as size, soma shape, action 
potential firing pattern, and laminar layer location. Interneurons can target other 
interneurons with inhibitory synapses onto other cells, usually occurring at the 
dendrites, just as for pyramidal neurons.  
Inhibitory interneurons have many functions, they must balance the excitation 
on different regions of a neuron, and only about 16% of pyramidal neuron synapses 
are from inhibitory interneurons (Markram, Toledo-Rodriguez et al. 2004). At certain 
inhibitory synapses there is less depression compared to excitatory synapses, allowing 
some interneurons to fire at higher frequencies (Galarreta and Hestrin 1998, Wang, 
Gupta et al. 2002). Inhibitory interneurons must be activated at the right moments, 
they must constantly be in balance, or else the network can become faulty. Any 
interruption of the normal balance can lead to disruptions in the normal functioning of 
the network.  
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The balance between excitation and inhibition is important when discussing 
inhibitory cells because in the end, these interneurons control the synchronization at 
certain frequencies (Konig, Engel et al. 1996, Markram, Toledo-Rodriguez et al. 
2004). The diversity seen in inhibitory interneurons is important for the maintenance 
of the brain’s connections. This regulation is important to guarantee the proper 
processing of stimuli in a given brain region in an unpredictable and ever changing 
environment (Markram, Toledo-Rodriguez et al. 2004).  
Inhibitory interneurons can be differentiated in many different ways, including 
staining methods and intrinsic firing properties (Connors and Gutnick 1990, 
Kawaguchi and Kubota 1995, Kawaguchi and Kubota 1996). Among peptides in the 
neocortex, vasoactive intestinal peptide (VIP) and somatostatin (SS) staining are 
expressed in different GABAergic cells (Demeulemeester, Vandesande et al. 1988, 
Rogers 1992, Kubota, Hattori et al. 1994, Kawaguchi and Kubota 1996). Parvalbumin 
(PV) stained interneurons are immunoreactive for the calcium binding protein PV. 
These three subtypes are the prominent inhibitory interneurons. SS interneurons have 
different roles in the cortical circuit (Kawaguchi and Kubota 1996). SS are mostly 
low-threshold spiking (LTS) neurons and PV interneurons are mostly fast-spiking (FS) 
interneurons (Markram, Toledo-Rodriguez et al. 2004). FS interneurons have lower 
input resistances and tend to spread horizontally and control horizontal activity 
(Gonzales-Burgos, Krimer et al. 2005). SS interneurons are found in the hippocampus, 
all throughout the neocortex, and tend to be more modulatory. They form synapses on 
the distal dendrites of pyramidal cells and spread vertically rather than horizontally 
(Kawaguchi and Kubota 1996).  
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Rosen et al. (1998) demonstrated that the numbers of PV-expressing neurons 
are decreased focally in deep layers, but another study that counted all GABAergic 
neurons showed there was no difference.  In normal cortex, PV interneurons are the 
stronger inhibitory cells (Hu, Gan et al. 2014), however, in the PMR, there are fewer 
PV interneurons, and they seem to no longer be the main inhibitory cells (George and 
Jacobs 2011). The Jacobs’ lab has used stereology to count numbers of SS, PV and 
VIP neurons. Within and surrounding the malformation, PV neuronal counts are down 
while SS and in some cases VIP neuronal counts are increased. We have hypothesized 
that the PV neurons are more vulnerable to the hypoxic insult while the SS neurons are 
resilient. It may be that homeostatic attempts to maintain cortical inhibition allow PV 
neurons and/or synapses to be replaced by SS neurons and/or synapses. This could 
account for SS interneuron increased strength within the PMR. All of these data 
together suggest that the interneuron subtypes are differentially affected.  
GABAergic interneurons contain many mGluRs that act on then by 
depolarizing them directly. The result of this is greater inhibition, wherever these 
synapses are made, which is on both excitatory and inhibitory interneurons (Zhou and 
Hablitz 1997). In addition, recent studies show that LTS interneurons, due to their 
electrically coupled networks, are suited to modulate cortical excitability (Gibson, 
Beierlein et al. 1999). LTS neurons in the PMR have been shown to have an increased 
maximum frequency when compared to LTS neurons in control tissue (George and 
Jacobs 2011). Additionally, a decreased firing frequency was seen in FS cells as 
compared to the LTS interneurons (George and Jacobs 2011).  Since the interneuron 
subtypes are maintained in the PMR, this suggests that differentiation normally 
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proceeds once the lesion is induced. It could also mean that the mechanisms 
underlying cell type definition are complete in layer V prior to lesion time (George 
and Jacobs 2011). The interneuronal subtypes can be affected in different ways in both 
animal models and in human tissue so these interneurons are useful to study  
(DeFelipe, Garcia et al. 1993, Buckmaster and Dudek 1997, Rosen, Jacobs et al. 1998, 
Powell, Campbell et al. 2003, Trotter, Kapur et al. 2006). We are interested in these 
interneurons because we believe that these inhibitory cells are the cause of the 
epileptiform activity seen in our model. We have previously shown via whole cell 
patch clamp recordings that the SS interneurons within the PMR receive more 
excitatory synaptic input and fire action potentials at higher maximal rates compared 
to control SS interneurons. This increased strength of these intracolumnar interneurons 
may synchronize excitatory activity within a column. In addition, increased strength 
from SS to other interneurons may produce network disinhibition. Since these 
Figure D. Changes in cortical inhibitory subtypes after 
malformation. In normal (control) cortex, the PV interneurons 
project horizontally and provide a powerful suppressant of 
horizontally (intercolumnar) excitatory activity. In contrast, the 
SS interneurons normally project intracolumnarly and provide 
weak or modulatory inhibition onto the dendrites of both 
excitatory and inhibitory neurons. In malformed cortex, 
specifically within the PMR, we hypothesize SS neurons are 
strengthened in function. This is supported by the increased 
excitatory synaptic activity they receive, the increased maximal 
firing and increased output (described below) determined 
optogenetically. This increased function of the inhibition may 
serve to both synchronize excitatory activity within a column and 
produce disinhibition due to the contacts onto PV interneurons. 
Reduced functioning of PV interneurons may then allow the 
spread of this synchronized excitatory activity across the cortex 
in the form of epileptiform activity. 
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interneurons project vertically, rather than horizontally like the PV interneurons, they 
synapse in multiple layers simultaneously. Since these vertical SS synapses are usually 
modulatory, they normally do not create robust synchrony. It has also been shown that 
in the presence of mGluRs, SS interneurons fire in an oscillatory manner and that 
activity can cause an increase in synchrony among the nearby pyramidal neurons 
(Connors and Gutnick 1990). It is the combination of these two normal processes 
(intracolumnar projection and synapses onto other inhibitory interneurons) with the 
strengthening of their function in the PMR that has led us to hypothesize that the PMR 
has an increase in intracolumnar synchrony. Overall, we hypothesize that PV 
interneurons that are normally strong become weakened in the PMR, while SS 
interneurons that are normally weak or modulatory become strengthened in the PMR 
(Figure D). 
There are two ways SS interneurons may be producing network excitation with 
their inhibitory synapses. They synapse onto the PV interneurons, and since they are 
inhibitory cells, we hypothesize more strongly in the PMR, they inhibit these 
inhibitory cells, which could lead to excitation. Secondly, since SS interneurons 
project vertically, they cause the synchronous inhibition and firing of pyramidal 
neurons. Normally, the SS interneurons are not powerful, but if they become very 
powerful, they can act to synchronize all activity, providing a jump start to 
epileptiform activity. It is important to localize the cause of this increased excitation to 
be able to better target neuronal and receptor subtypes for drug development (Jacobs, 
Hwang et al. 1999). What about these SS interneurons makes them more powerful in 
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the PMR? While previous studies have looked at inputs to these neurons, this project 
looks at the output from these specific subtypes utilizing optogenetics.  
1.4 Controlling inhibitory interneuron subtypes selectively 
Optogenetics is optical methods combined with genetic methods in order to 
achieve gain or loss of function of certain events on specific cells in living tissue 
(Deisseroth 2011). Optogenetics allows for targetable control tools that do three 
things: deliver effector function, respond to light, and enable technology for: 1) 
targeting the control tools in cells of interest; 2) electrical recording of evoked activity 
or other analysis; and 3) delivering light into the tissue that is under investigation 
(Deisseroth 2011). Neurons can be specifically controlled when they express proteins 
that are sensitive to light (LaLumiere 2011). Fenno et al. (2011) mentions that with 
this technology, we have been able to selectively mark SS interneurons with 
Channelrhodopsin (ChR), enabling us to activate these specific interneurons with blue 
light.  Type I rhodopsin combines light sensation and ion flux into one protein 
encoded by one gene (Fenno, Yizhar, & Deisseroth, 2011). Fenno et al. (2011) states 
that with light stimulation, the channel changes conformation and opens. In the 
absence of further light stimulation, it changes back to the closed conformation. 
Transgenic mice, as opposed to viral transfection of ChR, allow for greater control 
over transgene expression because of the use of large promoter fragments (Fenno, 
Yizhar, & Deisseroth, 2011). The optogenetic system dependent on Cre allows for a 
direct look at the neural activity of specific neuronal populations and their relationship 
with animal behavior (Fenno, Yizhar et al. 2011). In order to achieve the ChR 
expression on SS interneurons, we crossed Floxed stop codon on a ChR-2 expressing 
19 
 
gene in YFP reporter female mice with Cre recombinase in the 3' UTR of the 
somatostatin locus males. This allowed for the selective activation of the SS 
interneurons with blue light. We have recently shown with optogenetics that SS 
interneurons of the PMR produce more output than the same interneuron subtype in 
control (Figure E). We have also shown that epileptiform fields can be generated with 
light activation of SS interneurons alone (Figure F). This suggests that reducing the 
activity of SS interneurons may be an effective way to prevent epileptiform activity 
associated with microgyria. We can achieve this via control of metabotropic glutamate 
receptors. This is beneficial because the effectiveness of therapy is limited in about 
30% of all epilepsy cases, and these mGluRs are very good targets (Loscher, Dekundy 
et al. 2006).  
 
 
 
 
 
 
 
Figure E. IPSC produced by selective, optogenetic activation of SS interneurons. 
After mating Cre-SS mice with floxed-ChR mice, ChR is present selectively in SS 
interneurons (although there may be ~10% error (Hu, Cavendish et al. 2013)). Whole 
cell patch clamp recordings were made in layer V pyramidal neurons. Blue light 
(bLED) was applied through the 60X objective above the recorded neuron to activate 
the ChR in SS interneurons. Data shown is from the work of Nicole Ekanem in the 
Jacobs lab. A preliminary form of this data was published in the Masters’ thesis of 
Ekanem (2015). This data will serve as the untreated form to which the studies 
presented in the current Masters’ thesis will be compared. 
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The mGluRs are members of the G-protein coupled receptor super family 
(GPCRs) (Jong, Sergin et al. 2014). GPCRs are the largest members of membrane 
proteins; they also mediate a variety of cellular processes (Rosenbaum, Rasmussen et 
al. 2009). They are characterized by having seven helical membrane spanning regions 
(Rosenbaum, Rasmussen et al. 2009) and can interact with many second messengers. 
They can also be hindered by many different proteins. On the cell surface, mGluRs 
have GPCR independent signaling through β-arrestin and GPCR dependent signaling 
(Jong et al., 2014). β-arrestin blocks the receptor/G-protein interaction. This is an 
adapter protein that targets GPCRs for clathrin mediated endocytosis (Luttrell and 
Figure F. ChR-SS evoked epileptiform field potentials from ex vivo slices 
containing an induced microgyrus. At the arrow a 2 msec long pulse of blue light 
was applied through the 60X objective centered on layer V within the PMR (~0.25 
mm adjacent to the sulcus) in order to activate the ChR selectively genetically 
inserted in SS interneurons. Field potential recordings were made within layer V in 
the center of the applied light. The aCSF bath contained a low level (0.02 mM) of 
the GABAA receptor antagonist, Gabazine, in order to increase network excitability. 
This epileptiform field was not obtained from control slices under the same 
conditions, suggesting that only within the malformed cortex can activation of 
inhibitory interneurons produce this network hyperexcitation. These data collected 
by Weston, Ekanem and Jacobs and originally published as part of Nicole Ekanem’s 
Masters’ thesis (2015). 
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Lefkowitz 2002). The three main functions of β-arrestin are to aid in GPCR coupling 
efficiency, to sequester GPCRs, and to downregulate/re-sensitize GPCRs (Luttrell and 
Lefkowitz 2002). It can also recruit signaling proteins to GPCRs that are agonist 
occupied (Luttrell and Lefkowitz 2002). The mGluRs can act through phospholipase C 
(PLC) or adenylate cyclase (AC)  by coupling with GPCRs directly to ion channels or 
to second messenger cascades (Szydlowska, Kaminska et al. 2007).  
There are 8 different groups of mGluRs that are classified into three groups 
based on homology, pharmacological profile, and coupling to intracellular pathways 
(Lujan, Shigemoto et al. 2005). The three 3 different subgroups of mGluRs are named 
after their agonists.  
Group I mGluR modulates the inhibitory interneurons. Group I is made of 
homomeric receptors containing either subunit 1 or subunit 5 and are thus referred to 
as mGluR5 and mGluR1. Most agonists are not selective for mGluR1 or mGluR5, but 
there are very good antagonists that are selective. My thesis focuses on these Group I 
mGluRs, which are excitatory postsynaptic receptors (Jong, Sergin et al. 2014). Group 
I mGluRs are proconvulsive by increasing membrane excitability and are excitatory 
receptors that enhance neurotransmitter release, regulate inhibitory glutamate 
receptors (iGluR) responses, and control many depolarizing currents (Alexander & 
Godwin, 2006). Group I mGluRs are modulatory and act slowly via their G-protein 
and second messenger involvement (Alexander & Godwin, 2006). In addition, they 
are positioned in many areas that are only active under high neuronal activity 
conditions. The mGluR1 and mGluR5 null mice show no seizure behaviors 
(Alexander and Godwin 2006).  
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The mGluR5 are prominent in areas involved with emotion, motivation, 
learning, and memory, and also play a large role in many disorders and diseases, 
including epilepsy (Jong, Sergin et al. 2014). This receptor is a great target because it 
has been shown to be necessary for induction of epileptiform activity (Wong, Bianchi 
et al. 2005). As mentioned in Jong et al. (2014), it acts through Gq/11 and regulates 
cell function via transcriptional profile changes and modulating translation of dendritic 
mRNAs. It also has an orthosteric binding site on its cytosine rich domain and has 
allosteric binding sites that when bound by drug, decrease the activity of the main site 
or can have a neutral effect. Unlike mGluR1, mGluR5 does not experience ligand bias. 
Ligand bias refers to when a ligand keeps a unique conformation that triggers either a 
G-protein dependent or independent pathway. Intracellular signaling is present and is 
thought to be through the actions of β-arrestin. Intracellular signaling has been shown 
to be an evolutionarily conserved feature and has been shown in C. elegans and plants, 
suggesting that it must play some important role. Intracellular GPCRs can regulate 
many functions such as inflammatory responses, proliferation, and survival. For 
intracellular GPCRs, there are two uptake systems: through Na+ dependent excitatory 
AA (amino acid) transporters or via a cystine/glutamate exchanger (Jong, Sergin et al. 
2014).  
The mGluRs that are present in the postsynaptic membrane tend to mediate 
membrane properties via second messenger interactions, and when they are present on 
the presynaptic terminal, they aid in synaptic vesicle release (Alexander & Godwin, 
2006). Targeting this mGluR5 receptor could control glutamatergic signaling due to its 
modulatory functions for ongoing activity without interfering with the functioning of 
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ionotropic glutamate receptors (iGluRs) (Alexander & Godwin, 2006). It is thought 
that Group I mGluRs are unattractive targets because mice with a null mutation for 
mGluR1 or mGluR5 showed a disruption in cerebellar motor function and long term 
potentiation (LTP) (Alexander and Godwin 2006). These observations, however, were 
observed in normal, non FL animals. Previous work in our lab has shown the mGluR5 
is enhanced in its expression and in its activity in the PMR region in our FL model 
relative to its expression and function in control cortex (Figure 1.43A).  
In previous lab studies, antagonists targeting this receptor have been shown to 
affect LTS but not FS cells when recordings were taken in ex vivo slices in normal 
cortex. In the PMR, LTS neurons respond more to DHPG, a Group I mGluR agonist, 
than control neurons did (Figure H). In addition, the response to DHPG is only via the 
mGluR1 receptor in control, but the response in PMR is both mGluR1 and mGluR5. 
Targeting of the mGluR5 receptor will therefore be less likely to interfere with the 
Figure G. Expression of mGluR5 is increased within PMR compared to control 
cortex at both P16 and P2. Left panel: Example Western Blot data for mGluR5 
(subsequently normalized to b-Actin) for the PMR (1 mm circle of tissue through 
cortex taken ~0.5 to 1.5 mm lateral to the sulcus, in homologous control cortex, at ~ 
2.5 to 3.5 mm lateral to the sulcus (Lesion far) and in homologous control cortex. 
Right panel: Expression was quantified by digital measurement of the intensity from 
film exposed to the radioactive blots (NIH’s Image program). * = t-test, p< 0.05. 
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normal functioning tissue and hopefully only target the abnormal areas. We believe 
that the enhancement of this receptor on SS interneurons is the cause of the 
epileptiform activity seen in the FL model. We hypothesize that blocking these 
mGluR5 receptors will lead to a decrease in the excitation seen in the PMR region of 
our FL animals by decreasing the output of these SS interneurons. Not only do we 
hypothesize that this will inhibit the epileptiform activity, but we hypothesize that it 
will aid in other developmental disorders that have epilepsy as a co-morbidity. Since it 
has been shown that mGluR5 is increased in expression as early as P2 (Figure G), 
early treatment is suggested. To test this hypothesis, Gabapentin (GBP), a current 
antiepileptic drug (AED), and MTEP, an mGluR5 antagonist, will be used on PMR 
and control animals.  
 
 
 
 
Figure H. Effect of local application of mGluR1/mGluR5 
agonist DHPG (0.01 mM) on IPSCs recorded in layer V 
pyramidal neurons of control (yellow) and PMR (purple) 
cortex. In control neurons, DHPG cause nearly a doubling 
in the frequency of IPSCs, while in the PMR it caused more 
than a tripling of the IPSC frequency. Numbers of recorded 
neurons shown lower part of the bars. * = t-test, p< 0.05. In 
additional experiments it was demonstrated that bath 
application of an mGluR1 antagonist prevented the 
increased IPSC frequency associated with local DHPG in 
controls but not in the PMR. Under these conditions, bath 
application of an mGluR5 antagonist eliminated the 
increase in the PMR. Work from George and Jacobs. 
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1.5 Potential treatments for malformation-associated epileptiform activity 
GBP will be used to test whether it can block the early development of 
epileptiform activity, as well as whether it changes the increased output from SS 
neurons. It is a current anticonvulsant that has structural analogy to GABA (Kim, 
Chang et al. 2009). It can be administered at therapeutic doses, unlike other AEDs that 
have to be slowly introduced into the system (R. Fisher & Saul, 1997). GBP has a lack 
of drug interaction, is cleared by the kidney, and exhibits minor side effects compared 
to most anticonvulsants (R. Fisher & Saul, 1997). In addition, GBP has not been 
shown to have any long term effects during development (Martin, McClelland et al. 
2002). On the other hand, it does have a short-half life and is mainly used as an add-on 
medication to other anti-seizure medications (Fisher and Saul 1997). GBP blocks the 
influx of calcium into neurons (Traa, Mulholland et al. 2008 ) by blocking the 
interaction of TSP and α2δ-1, a calcium channel subunit (Figure I). This is the 
receptor for TSP mediated synaptogenesis (Eroglu, Allen et al. 2009, Andresen, 
Hampton et al. 2014). TSP 1/2 is expressed during the postnatal period when many 
excitatory synapses are forming. TSP is not present in the adult brain when excitatory 
synapses are greatly reduced (Eroglu, Allen et al. 2009). α2δ-1 is an accessory subunit 
of voltage gated calcium channels and aids in membrane trafficking (Andresen, 
Hampton et al. 2014), affects the voltage dependence of activation, and also affects the 
increase in current amplitude activation and inactivation kinetics (Arikkath and 
Campbell 2003). These channels can also influence other channels (Andresen, 
Hampton et al. 2014). GBP inhibits voltage gated calcium channel (VGCC) trafficking 
and directly inhibits calcium currents, this causes GBP to exert inhibitory effects on 
intracellular α2δ subunits (Hendrich, Tran Van Minh et al. 2008). All in all, α2δ-1 
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mediates important functions physiologically and the loss of this subunit can have 
severe consequences on functions relying on calcium channel trafficking and calcium 
currents (Arikkath and Campbell 2003). As mentioned in Andresen et al. (2014), this 
subunit’s role in synaptogenesis, however, is independent of the calcium channel. 
Treatment with GBP for inflammation such as in multiple sclerosis prevents injury-
induced excitation as well as a decrease in the amount of reactive astrocytes. It also 
decreased excitatory input onto layer V pyramidal neurons when used as a treatment in 
the FL model. GBP seems to eradicate most of the pathologies that are associated with 
the FL model, such as hyperexcitability, both in vivo and in vitro (Andresen, Hampton 
et al. 2014). Even though GBP prevents formation of excitatory synapses in vitro and 
in vivo, it does not affect already formed synapses; since there is a treatment window 
of 1 week that it is effective (Eroglu, Allen et al. 2009). It is unknown at this point 
whether GBP affects interneuron function.  
Figure I. Gabapentin blocks the interaction of thrombospondin and a2d-1 calcium 
channel subunit, thereby preventing excitatory synapse formation. Figure from Stahl, S. 
et al. (2013).  
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When mGluR5 is expression is enhanced, an antagonist could be used (Wong, 
Bianchi et al. 2005) to reduce activity to normal levels. This is why we chose to test 
MTEP, an mGluR5 antagonist as a potential treatment for the epileptiform activity 
occurring in the PMR. The mGluR5 produce effects through a number of intracellular 
signaling pathways (Figure J). The mGlu5 receptors play a role in proper 
development, because if it is knocked out, barrels do not form due to interruption of 
the mGlu5 signaling through PLC-β1 (Hannan, Blakemore et al. 2001).  A barrel is a 
specific anatomical unit in layer IV that represents an individual whisker (Woolsey 
and van der Loos 1970). These barrels make up a somatotopic map in the primary 
somatosensory cortex (Petersen 2007). Barrels allow for the delineation of functional 
organization, plasticity, and development (Petersen 2007). When sensory information 
is received, it is processed within the barrels depending on the whisker-related 
behavior (Petersen 2007).  As previously stated, our model shows an excess of the 
mGluR5 receptor in PMR tissue as early as P2. There are other mGluR5 antagonists, 
such as MPEP that have been previously used. We chose MTEP over MPEP because 
MTEP has been shown to have a greater selectivity for the mGluR5 receptor and is 
also more highly selective for mGluR5 without having effects on other mGluR 
subtypes as compared to MPEP (Colmers, Lukowiak et al. 1987, Lea, Movsesyan et 
al. 2005, Domin, Kajta et al. 2006, Lea and Faden 2006). Additionally, MTEP has 
shown to be more potent in vitro and in vivo (Szydlowska, Kaminska et al. 2007). 
MPEP has been shown in rodents and in Xenopus laevis oocytes expressing rat AMPA 
receptors to affect both AMPA and NMDA receptors (Gasparini, Lingenhohl et al. 
1999, Olive, McGeehan et al. 2005, Lea and Faden 2006). MPEP has also been known 
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to have electrophysiological effects on subtypes of NMDA receptors and kainate 
receptors (Lea and Faden 2006). MTEP has been shown to be effective at low doses 
and also does not have an effect on NMDA receptors, AMPA receptors, or kainate 
receptors (Cosford, Tehrani et al. 2003, Slassi, Isaac et al. 2005, Lea and Faden 2006, 
Loscher, Dekundy et al. 2006, Nagal, Greco et al. 2015). In addition, as discussed in 
Nagal et al., MTEP has a higher potency in human cloned receptors as compared to 
MPEP. It has also been shown to penetrate the blood brain barrier well. At 
behaviorally active doses, MTEP produces complete occupancy of the mGluR5 
receptor, and based on in vitro affinity, also produces brain free concentrations high 
enough to occupy the receptor (Nagal, Greco et al. 2015). Together these data suggest 
that blockade of mGluR5 receptors may be an effective means to reducing 
epileptiform activity associated with microgyria. We expect that chronic blockade will 
Figure J. Intracellular 
signaling pathways 
activated by mGlu5 
receptors. Pink X shows 
the expected effect of 
blocking with the MTEP 
antagonist. Some 
molecules will be 
increased while others 
will be decreased. 
Figure from Levenga, 
de Vrij et al. (2010) 
igure J. Intrace lular 
signaling path ays 
activated by lu5 
receptors. Pink X sho s 
the expected e fect of 
blocking ith the TEP 
antagonist. So e 
olecules i l be 
increased hile others 
i l be decreased. 
Figure fro  Levenga, 
de Vrij et al. (2010) 
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have no effect on interneurons in controls, because these receptors are not active on 
controls.  Therefore treatment should be selective on extra function in PMR.  
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Chapter 2 
Potential Treatments for Malformation Associated Epilepsy 
2.1: Hypothesis and Objectives 
Polymicrogyria, a developmental cortical malformation, can cause intractable 
epileptic seizures in affected individuals. This disorder has a lack of therapeutic 
treatments and drives a need to determine the underlying cellular mechanisms of cortical 
malformations also causing intractable seizures.   
These studies utilize a freeze-lesion model for polymicrogyria in transgenic mice 
that selectively express ChR channels on a particular interneuron cell type. These cells, 
within an epileptogenic area adjacent to the malformation known as the paramicrogyral 
region, are thought to be functionally altered as compared to control cortex, and have 
been shown to contribute to the epileptiform activity seen in the PMR/FL mice. Past 
studies have implicated the mGluR5 receptor as the cause of the over activation of these 
SS interneurons. This mGluR5 receptor is enhanced in its expression on SS interneurons 
in the PMR region, but not in control tissue.  
We hypothesize that blockade of the mGluRs will decrease the activity of SS 
interneurons and thereby prevent the generation of epileptiform activity and increased SS 
output in malformed cortex. With the following series of experiments, we assessed this 
by: 
1. Evaluating if the drug-treated mice (GBP or MTEP) showed suppressed 
epileptiform fields in drug-treated PMR vs drug-treated sham-lesioned control 
animals.  
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2. Evaluating the output of the SS interneurons in our 4 treatment groups 
(control-GBP, PMR-GBP, control-MTEP, PMR-MTEP) via whole cell patch 
clamping of pyramidal neurons with the use of optogenetics.  
All recordings were taken from pyramidal neurons in the designated PMR region 
or homologous control cortex.  
2.2: Materials and Methods 
Mice 
In order to achieve the ChR expression on SS interneurons, we crossed Floxed 
stop codon on a ChR-2 expressing gene in YFP reporter female mice with Cre 
recombinase in the 3' UTR of the somatostatin locus males. This allowed for the selective 
genetic insertion of ChR into SS interneurons, subsequently allowing activation of the SS 
interneurons with blue light application. Mice are housed in IACUC approved housing 
and all procedures and protocols are IACUC approved.  
FL surgery 
On postnatal day 1, aseptic surgery techniques were followed to induce the 
transcranial freeze lesions. SS-ChR2-EYFP mice were anesthetized by being placed in 
ice for 3 minutes to induce hypothermia. A coronal incision was made across the skull to 
expose it. A frozen probe consisting of a copper bar with a 0.1mm pointed tip cooled with 
dry ice to -55˚C was placed on the surface of the skull for 5 seconds on each hemisphere 
(bilateral lesion) approximately 0.5 mm from the midline. After surgery, the incision was 
sutured on the center and Vetbond glue was applied to the rest of the incision. Antibiotic 
ointment was then applied to the whole suture and the mice were then placed in a heating 
blanket and allowed to re-warm to normal body temperature. Pups were then returned to 
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their mother. The pups were weighed for five days following the surgery to ensure they 
gained weight and therefore had a proper recovery.  
 
SHAM surgery 
This surgery comprised of the same series of events as the FL surgery, however, 
instead of the freezing probe cooled to -55˚C, the probe was room temperature.  
Drug administration 
Freeze-lesioned and control (sham-lesioned) mice were all given one of two 
drugs, MTEP or Gabapentin. From postnatal day 1 through postnatal day 7 (P1-P7), the 
MTEP groups were given daily i.p. injections (at the same time each day) at a 
concentration of 10 mg/kg MTEP. For the GBP groups, the same protocol was followed 
(daily i.p. injections from P1-P7) at a concentration of 200 mg/kg. Because only a small 
volume can be injected into mice pups, for drug injections, the volume was held constant 
(within a small range) while the mg/ml of the drugs were varied according to animal 
weight. For MTEP a volume of 0.02 mls was used. Due to the lower solubility of GBP, it 
was necessary to vary this from 0.02 ml for P1-3, 0.03 for P3-5; and 0.04 for P5-7. 
Brain extraction and slice preparations 
Mice were anesthetized with isoflurane in a small chamber. Once overdosed, they 
were decapitated. After decapitation, the brain was excised and quickly removed and 
placed into cold (-18˚C) sucrose slicing solution containing (in mM): (2.5 KCl, 1.25 
NaH2PO4, 10 MgCl2, 0.5 CaCl2, 26 NaHCO3, 234 sucrose, 11 glucose). The brain was then 
transferred to a flat surface and sliced mid-sagittally. One side of the brain was frozen 
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and stored in a -80˚C freezer to save for later determination of mGluR5 protein levels in 
the brain tissue using Western blot techniques. The other half was placed on the 
vibratome stage and 300 µm coronal slices from the somatosensory cortex were taken 
using a 1000 plus vibratome. Slicing occurred while the brain was in the sucrose slicing 
solution. Somatosensory cortex was confirmed by using hippocampal morphology 
Figure K. Images from the 
Allen Brain atlas showing the 
location of primary 
somatosensory cortex (dark 
green, arrows).  Website: © 
2015 Allen Institute for Brain 
Science. Allen Mouse Brain 
Atlas [Internet]. Available 
from: http://mouse.brain-
map.org. Because there is far 
less somatosensory cortex 
present in sections with 
ventral hippocampus, only 
slices anterior to this level 
(equivalent to top and middle 
image) were used for both 
field potential and patch 
clamp recordings. 
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(Figure K). After slicing, the slices were transferred to a warmed holding chamber filled 
with artificial cerebral spinal fluid (aCSF) infused with 95% O2/5% CO2 to maintain pH.  
ACSF is comprised of (mM): 126 NaCl, 3.5 KCl, 1.25 NaH2PO4, 1.0 MgSO4, 1.2 CaCl2,10 
glucose, and 26 NaHCO3. Slices remained in the heated chamber of 34˚C for 25 minutes, 
after which the heater was turned off and the slices cool to room temperature over 20-30 
minutes. Slices were kept at room temperature until used for the patch and field 
recordings. 
Patching and Field recordings  
Before recording, the slices were transferred from the room temperature bath into 
the recording chamber with continuously flowing aCSF (~300 mOsm) infused with 95% 
O2/5% CO2 that was heated to 32˚C. In all instances, the aCSF contained 50 μM 2-amino-
5-phosphonopen- tanoic acid (APV), an NMDA antagonist, and 20 μM 6,7-
Dinitroquinoxaline-2,3-dione (DNQX), an AMPA and kainate antagonist. A high 
chloride intracellular solution was used (in mM: 70 K-gluconate, 10 Hepes, 4.0 EGTA, 
70 KCl, 4.0 Na- ATP, and 0.2 Na-GTP) in the glass pipette for the pyramidal recordings 
(~3-5 mOhms). Osmolarities and pH of both intracellular solutions were adjusted to 280-
290 mOsm and pH 7.3. Biocytin (0.5%) was included in recording pipettes to confirm 
neuronal morphology post-experiment via subsequent staining (25mg of biocytin was put 
into 5mL of high Cl- solution).  
In malformed cortex, the sulcus could be easily visualized under standard DIC 
optics. In these slices recording locations were chosen within the PMR, 0.25 – 0.5 mm 
adjacent to the sulcus or for controls, in homologous cortex (see Figure 1).  In all cases 
the recording location was within somatosensory cortex. 
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In the patch clamping experiments, an electrical stimulus was applied 100-150 μm 
lateral to the patched cell using a glass pipette filled with 1 M NaCl. Optical stimulation 
of the pyramidal cells was achieved using X-cite and XLED1 software (Lumen 
Dynamics) with the light applied through the 60X objective. To activate ChR expressing 
SS interneurons, a wavelength of 460 nm was used at an intensity of 100% (Figure L). 
Figure L. Cartoon illustrating the orientation of and interactions between three 
cortical neuronal subtypes discussed in this manuscript. SS are the normally weak 
or modulatory, dendrite-targeting inhibitory interneurons that have ChR 
genetically inserted to produce depolarization when blue light is applied B). PV 
are powerful inhibitors synapse on somata and preventing horizontal propagation 
of excitatory activity. Pyr = pyramidal neurons that are the main excitatory 
elements within the cortex. They have long apical dendrites. The layer V pyramidal 
neurons have axons that project not only subcortically, but also intracortically 
over long horizontal distances, particularly within layer V. The other green 
synapses (onto pyr) indicate thalamocortical and callosal excitatory afferents. 
Cartoon developed and modified by KM Jacobs. Here shown modified from that 
presented in Nicole Ekanem’s Masters’ thesis. 
ig re . artoon illustrating the orientation of and interactions bet een three 
cortical neuronal subtypes discussed in this anuscript. SS are the nor ally eak 
or odulatory, dendrite-targeting inhibitory interneurons that have h  
genetically inserted to produce depolarization he  l e li t is lie  ).  
are po erful inhibitors synapse on so ata and preventing horizontal propagation 
of excitatory activity. yr  pyra idal neurons that are the ain excitatory 
ele ents ithin the cortex. hey have long apical dendrites. he lay r  r i l 
neurons have axons that project not only subcortica ly, but also intracortically 
over long horizontal distances, particularly ithin layer V. The other green 
synapses (onto pyr) indicate thala ocortical and ca losal excitatory a ferents. 
artoon developed and odified by  Jacobs. ere sho n odified fro  that 
presented in icole kane ’s asters’ thesis. 
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These wavelengths were applied through a 60X objective either above the patched cell or 
100-150 μm lateral to the patched cell above the stimulating electrode, which was a 
second condition recorded. MultiClamp 700B Amplifier (Molecular devices) was used 
and the signal was digitized with pClamp software and a Digidata1440A (Axon CNS 
Molecular devices).  
For field potentials not requiring optical stimulation, the recording electrode was 
filled with either aCSF or 1 M NaCl. In these experiments, a stimulating electrode was 
placed in layer V and a recording electrode was placed in layer II/III. An ER1 amplifier 
(Cygnus Technologies) was used and the signal was digitized with pClamp software and 
a Digidata 1322A (Molecular Devices). 
Protocols 
Utilized protocols were as follows: (1) A series of increasing light durations in 
milliseconds (0.1, 0.2, 0.3, 0.4, 0.5, 0.5, 0.6, 0.7, 0.8, 0.9, 1, 2) was applied to determine 
the effectiveness of SS interneurons in producing IPSCs within the recorded pyramidal 
neuron with blue light alone. The series was repeated for a total of 3 presentations. The 
responses were averaged across the 3 presentations prior to measuring amplitude, 
duration, and area of the light-evoked inhibitory postsynaptic current (IPSC). Finally in 
cells, (2) the recording was switched from voltage clamp to current clamp mode and a 
series of hyperpolarizing and depolarizing steps applied (400 msec duration, beginning at 
-200 pA and stepping at 10 pA for a total of 70 steps), in order to measure intrinsic and 
cellular properties, and confirm the electrophysiological cell type. 
Field potential recordings were made in layers II/III, directly above an electrical 
stimulating electrode located in deep layers. Care was taken to make sure that recording 
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and stimulating electrodes were vertically aligned and perpendicular to a tangent at the 
pia above the recording site. Threshold current level in these experiments was that 
evoking a short latency negative field of 0.2 mV peak amplitude with an electrical 
stimulus of 0.02 msec duration. (3) An Epitest at half-threshold (10 sec between stimulus 
presentations) was then run to test the incidence of epileptiform activity, 10 stimulus 
presentations at half-threshold current were given. (4) Then, an Epitest exactly as that 
described above, except at threshold intensity was run. (5) An intensity series was applied 
by maintaining the current while varying the duration of the electrical stimulus (0.02, 
0.04, 0.08, 0.16, 0.32 msec), with the series repeated three times.  (6) Lastly, a paired 
pulse stimulation was applied with paired electrical stimulations at varying durations of 
electrical stimulation (0.02, 0.04, 0.08, 0.16, 0.32 msec). Because slice health varies, for 
field potential recordings in order to be included for analysis, the slice had to meet three 
criteria: a) A threshold current of 10 mA or less; b) an increasing peak amplitude of the 
short latency field negativity with increasing stimulus intensity; and c) at maximum 
stimulus intensity, the short latency field negativity must have a peak amplitude of at 
least 0.6 mV. Over many years the Jacobs’ lab has found these to be reliable criteria for 
detecting slice health.  For patch clamp experiments, mostly the visual appearance of the 
neurons was used as an indicator of health, where unhealthy slices had many cells with 
swollen soma, nuclei positioned to the side of the slice and unclear membrane borders. It 
is not possible to obtain patch clamp recordings from this type of unhealthy neurons, thus 
other criteria thus far have been unnecessary. 
 
 
38 
 
Immunohistochemistry 
Field potential and patch clamp slices were immediately placed in 4% 
paraformaldehyde for 24 hours after recording. After this 24 hour period, slices were 
placed in phosphate buffer saline (PBS) until staining. Whole-cell patch clamp slices with 
biocytin-filled cells were stained with Avidin (1:500 Texas Red conjugate, Life 
Technologies) or with Avidin and NeuN (mouse anti-NeuN conjugated with Alexa Fluor 
488, Chemicon MAB377X). Images of the stained pyramidal cells were taken with the 
Zeiss LSM 710 confocal laser scanning microscope. Microscopy was performed at the 
VCU Microscopy Facility, supported, in part, by funding from NIH-NCI Cancer Center 
Support Grant P30 CA016059. Images of the slices stained with Avidin and NeuN were 
obtained with the Scope A1 microscope (Zeiss) and Image Pro Premiere 9.1 (Media 
Cybernetics).  
Data analysis 
Data was analyzed using Clampfit (Axon Instruments) and home-written macros 
in Microsoft Excel. Data are presented as mean ±SEM. Statistical analysis was performed 
with two-way repeated measures ANOVAs SPSS software (IBM), for measures across 
intensity series and with z-tests for measures of proportion. For the 2-way ANOVAs, 
stimulus intensity was the repeated measure, and subject group was the second measure. 
In all cases, significance was set to p<0.05. Throughout the results the current data is 
compared to that from untreated animals (both naïve controls and PMR).  In all cases all 
data from untreated animals was collected by Nicole Ekanem and Laura Reed and was 
presented in a preliminary form in the Masters’ thesis of Nicole Ekanem (2015). 
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Chapter 3 
Results 
3.1 Freeze-lesion histopathology not changed by drug administration 
To determine whether the application of drugs altered the cortical lamination 
of either control or the histopathology of the PMR, slices were 
immunohistochemically stained for NeuN. Slices were chosen that contained anterior 
to approximately mid-way through the dorsal hippocampus, as these slices contained 
the most primary somatosensory cortex (top two pictures in Figure K). After treatment 
with either MTEP or GBP, the cortical lamination was similar to that in sections from 
untreated mice, as shown in Figure 1. In control, sham-lesioned mice, the normal six 
layers of neocortex were visible in sections through somatosensory cortex (Figure 1 
D-F). In freeze-lesioned mice, sections showed the abnormally-laminated microgyrus 
Figure 1. Lamination within somatosensory cortex for both malformed (A-C) 
and control brains (D-F), identified with NeuN staining. In each case the red 
outlined box shows approximate recording location, with layers indicated. For 
malformed brains, location is within the PMR, 0.25 – 0.5 mm adjacent to the 
sulcus. A) Non-drug FL; B) MTEP FL; C) GBP FL; D) non-drug naïve control; 
E) MTEP sham; F) GBP sham. Scale bar in F for A-F = 0.2 mm. 
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and adjacent six-layered PMR region within somatosensory cortex. Treatment with 
either MTEP or GBP did not qualitatively change the histopathology nor the 
cytoarchitecture of the adjacent, six-layered PMR region from which recordings were 
made (Figure 1 A-C). 
3.2 Network activity measured with field potential recordings 
To determine if the treatments with either MTEP or GBP affected the network 
excitability, field potential recordings were made from layer II/III during stimulation of 
deep layers directly beneath the recording site within somatosensory cortex and the PMR 
(~0.5 mm adjacent to the sulcus). Under these conditions threshold level is determined by 
adjusting the current level applied with a 0.02 msec pulse until a short latency negativity 
of 0.2 mV peak amplitude is obtained. A test for epileptiform activity was then performed 
by presenting 10 stimuli (10 sec interval) at half-threshold and subsequently repeating this 
at threshold. While an objective quantifiable epileptiform detection system is desirable and 
under development in the Jacobs lab, it was not available to assess these data.  Instead, the 
expertise of the lab PI (KM Jacobs) was used to identify the presence of epileptiform 
activity, which has the following characteristics: 1) all-or-none behavior (that is, it is not 
graded with stimulus intensity); 2) variable form; 3) variable latency; 4) typically long 
latency relative to that of the short latency response which does vary with stimulus 
intensity. Only polyphasic deflections at least 2 x the baseline noise were identified as 
epileptiform events (Figure 2). Ictal (seizure) –like activity has a large slope and short time 
to peak, extremely short peak and often repeated instances of these ictal ‘spikes’. In 
contrast, interictal-like activity is typically lower in amplitude with a much more slowly 
rising peak, a longer duration peak, and greater presence of polyphasic activity. For all 
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subject groups studied here, in most cases the epileptiform activity observed was interictal-
like, although there were a few instances of ictal-like activity (Figure 2 C, I). In the 
Figure 2. Examples of epileptiform activity evoked with low stimulus intensity for 
different subject groups. Small blue arrows indicate time of stimulation. In all 
cases the black trace is an example of epileptiform activity; and the thinner gray 
trace shows a non-epileptiform response to the same stimulus presentation (from 
the same file). This demonstrates the all-or-none behavior of the epileptiform 
activity. A, B) Non-drug-treated controls from two different animals (A and B). 
Some epileptiform activity in controls is normal for this age group (P12-21 in 
rodent). C, D) Non-drug-treated PMR responses were typically larger than those 
observed in controls. C and D from two different animals. E) MTEP-treated sham 
control. F) MTEP-treated PMR. For all responses from MTEP-treated mice, 
epileptiform activity was qualitatively similar to that in un-treated controls. G) 
GBP-treated sham control. H, I) GBP-treated PMR. Ictal-like activity was 
observed only in non-drug-treated PMR (C) and in GBP-treated PMR (I). Vertical 
scale bar = 0.15 for A-H; and 0.45 for I. 
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counting of instances of epileptiform activity, both ictal-like and interictal-like were 
counted as epileptiform activity. 
In untreated mice, even controls within the age group tested (P21-21) normally 
have some hyperexcitability (Luhmann and Prince 1990). However in untreated 
freeze-lesions, the incidence of epileptiform activity is much higher within the PMR 
than in homotopic regions of control cortex, whether measured per mice or per slice 
(Figure 3). Surprisingly, controls treated with MTEP had a high rate of epileptiform 
activity incidence, similar to untreated PMR mice. The epileptiform incidence per 
slice from PMR mice treated with MTEP was significantly lower than that for slices 
from the control-MTEP-treated mice (Figure 3B, z-test, p<0.05). In addition, the 
epileptiform incidence per slice was significantly lower for PMR-MTEP compared to 
that in the PMR-untreated group (one-tailed z-test, p<0.05; with two tails, p =0.08). 
Here a one-tailed test was applied because of the expectation that the treatment would 
reduce the epileptiform incidence. 
For treatment with GBP, incidence of epileptiform activity per slice was 
similar to that in slices from untreated mice. That is, control-GBP was similar to 
untreated controls and PMR-GBP was similar to untreated PMR. Like their untreated 
counterparts, for GBP-treated mice the epileptiform incidence per slice was 
significantly higher for PMR compared to control mice (z-test, p<0.05). 
When epi incidence was examined per mouse, although the bars appear higher 
for all drug-treated animals, the incidence was not significantly different from 
untreated controls (z-tests, p>0.05), likely due though to low subject numbers.  In 
future experiments, we expect to obtain at least 9 mice per group. 
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3.3 Pyramidal neuron identification/differentiation  
Neuronal morphology 
To choose the neurons from which recordings would be made, the patch 
electrode was first directed to layer V under low power. It was expected (and 
subsequently confirmed) that layer V would make up the 3rd quadrant deep to the pia. 
Under high power and DIC optics, the desired pyramidal neurons were identified 
morphologically as the ones having large soma; but were most easily distinguished by 
the large apical dendrite that extended to superficial layers. No other cell types has this 
apical dendrite. These morphological characteristics were confirmed for some neurons 
with post-hoc avidin staining of the biocytin that had diffused into the cell via the 
patch pipette, during the recording (Figure 4). It is possible that FL and/or drug-
treatment will change detailed characteristics of the pyramidal neuron morphology 
such as branch length or number. However the main characteristic of the apical 
dendrite was confirmed for at least some neurons in all subject groups (Figure 4). 
Figure 3. Incidence of evoked 
epileptiform activity recorded 
from field potentials in ex vivo 
slices and analyzed both per 
mice (A) and per slice (B). 
Subject group is indicated 
under each bar. The number of 
either mice (A) or slices (B) is 
shown in the bar for each 
subject group. * = z-test, 
p<0.05. To truly evaluate the 
per mice results, likely 
additional subjects must be 
investigated. 
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3.4 Optogenetic activation of IPSCs from tissue containing ChR in SS interneurons 
        When blue light was applied via an LED (bLED) through the 60X objective, in 
tissue containing ChR in SS interneurons, IPSCs were evoked in pyramidal neurons 
Figure 4. Confirmation of pyramidal neuronal type for recorded neurons. Biocytin 
was included in the recording pipette and its presence subsequently identified in the 
fixed tissue with the application of a fluorescent avidin to which the biocytin binds. 
Here the large somal size and presence of an apical dendrite (indicated with pink 
arrows) projecting toward the pia (yellow arrow) indicate that these are pyramidal 
neurons. Not every recorded neuron can be labeled, but these examples indicate that 
the neurons targeted in the live slice were correct. Images were taken as maximum 
projections after a depth profile on a Zeiss confocal microscope. A) Non-drug 
control; B) GBP-FL; C) Non-drug FL; D) GBP-sham control. Scale bar in D for A-D 
= 0.02 mm. 
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(Figure 5). Responses were evoked at a relatively short latency and in a graded fashion.  
That is, increasing the duration of the light to produce a more intense stimulus caused an 
increase in the peak amplitude of the IPSCs for all subject groups (shown for MTEP- and 
GBP-treated animals in Figure 5). IPSCs were qualitatively similar between all subject 
groups. 
3.5 The effect of MTEP treatment on SS-ChR IPSCs in control cortex 
Does MTEP treatment change the SS-ChR IPSC in controls? 
For all studies on the IPSCs three measures will be presented: peak amplitude; 
area of the significant response (defined as two standard deviations above the mean of 
the baseline, which is the region prior to stimulation for each voltage clamp 
Figure 5. Examples of IPSCs evoked by the application of blue light (bLED) in tissue 
with ChR in SS interneurons. Recordings are from pyramidal neurons during 
activation of SS inhibitory interneurons. A) Sham-injured mouse treated with MTEP; 
B) FL mouse treated with MTEP, with recordings made within the PMR; C) Sham-
injured mouse treated with GBP; D) FL mouse treated with GBP, with recordings 
made within the PMR. Three intensities are shown: for A & B: 0.3 (brown), 0.4 
(green), and 0.8 (blue) msec of light; and for C& D: 0.3 (brown), 0.5 (green), and 0.8 
(blue) msec of light. 
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recording); and duration of the significant response. Each measure is plotted against 
the 11 stimulus intensities (duration of bLED in msec). The plots for the comparison 
between untreated controls and MTEP-treated controls are shown in Figure 6. To test 
for significant differences, a 2-way repeated measure ANOVA was used with stimulus 
intensity as the repeated measure. For this comparison, recordings were made from 19 
untreated control and 11 control – MTEP treated neurons. There was no significant 
effect of subject group or stimulus intensity, however there was a significant 
interaction of these two (p=0.01, see Table 1, where all p values are reported for 
comparisons shown in Figs. 6-9). For post hoc analyses of the interaction between 
subject group and stimulus intensity, in all cases a 1-way ANOVA was performed at 
Figure 6. Comparison of the SS-ChR 
evoked IPSC between untreated 
(naïve) controls (black, N = 19) and 
MTEP-treated sham-injured controls 
(purple, N = 11). Does MTEP alone 
have an effect? IPSCs were recorded 
in layer V pyramidal neurons in 
tissue with ChR selectively in SS 
interneurons. Stimulus intensity was 
generated via increasing durations of 
bLED. The IPSC peak amplitude (A), 
area of significant response (B), and 
duration of significant response (C) 
are shown here. Significance was 
tested with a 2-way repeated 
measures ANOVA.  For peak and 
area, there was no significant 
difference between subject groups 
and no significant interaction 
between subject groups and stimulus 
intensity.  * = significant difference 
assessed with post hoc analysis. See 
text and Table 1 for all p values. 
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each stimulus intensity, with the p value adjusted with a Bonferroni correction 
(0.05/number of comparison tests). In this case there were 11 stimulus intensities, so 
in order to reach significance at any one level, the p value had to be less than 0.045 
(0.05/11). After applying these criteria, there was no significant difference in the peak 
IPSC between control-untreated and control-MTEP at any stimulus level. 
The area of the IPSC was not significantly different for MTEP-treated 
compared to untreated controls, there was also no effect of stimulus intensity and the 
interaction was also not significant (see table 1). For IPSC duration, there was an 
effect of group, an effect of stimulus intensity, and an interaction (p<0.05). To further 
examine the interaction, 1-way ANOVAs were performed at each level, with a 
Bonferroni adjustment to the p value needed for significance.  After applying this 
correction, there was a significant difference between control-untreated and control-
MTEP only at 0.2, 0.3 and 0.4 msec stimulus intensity levels, as shown by asterisks in 
Fig. 6. 
3.6 Does MTEP prevent the PMR-associated increase in SS-ChR IPSC peak? 
To determine if MTEP could prevent the PMR-associated increase in the peak 
of the IPSC evoked with optogenetic activation of SS interneurons, we first compared 
the results between control-MTEP and PMR-MTEP groups. Should MTEP be 
effective, it was expected that there would no longer be a significant difference 
between control and PMR when both were treated with MTEP. That was in fact the 
case, based on a 2-way ANOVA for just these groups (subject groups N.S. different, 
p>0.05). However it is possible that even without a significant difference that MTEP 
was not returning the SS interneuron output to the normal (untreated control) levels.  
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To examine this further, the results for four groups: control-untreated (19 
neurons), PMR-untreated (14 neurons), control-MTEP (11 neurons) and PMR-MTEP 
(11 neurons, see Figure 7) were compared. For IPSC peak, although there was no 
effect of subject group with the 2-way repeated measures ANOVA, there was a 
significant effect for stimulus intensity and a significant interaction between stimulus 
intensity and subject group (p<0.05). To determine which subject groups were 
significantly different for which intensities, 1-way ANOVAs with Bonferroni 
correction to the p-value were used (as described above). This analysis showed a 
significant group effect for three intensities: 0.2, 0.3, and 0.4 msec. Bonferroni post  
 
 
Figure 7. Does MTEP prevent 
the enhanced SS-ChR IPSC 
associated with the PMR? All 
features are the same as for 
figure 6, with 14 PMR-
untreated neurons and 11 PMR-
MTEP neurons. There was a 
significant interaction between 
subject group and stimulus 
intensity on all measures (two-
way repeated measures 
ANOVA, p<0.05).  MTEP 
treated groups were larger than 
untreated groups at low 
intensities. See text and Table 1 
for further explanation of 
significant effects. 
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hoc analysis of this result showed that the PMR-MTEP group was significantly larger 
than the control-untreated and PMR-untreated groups at all three intensities. 
It is however clear that to draw firm conclusions, additional data will be 
necessary, given the large error bars and low power (see power in Table 1) associated 
with the current data. Results for IPSC area were similar to those for IPSC peak with 
significant effects of stimulus intensity and the interaction between subject group and  
stimulus intensity. The post hoc analysis showed that only at 0.2 msec was there a 
significant difference, where PMR-MTEP was once again greater than both control-
untreated and PMR-untreated. For the IPSC duration the results were similar to that 
for peak.  The 2-way repeated measures ANOVA showed a significant effect of 
stimulus intensity and a significant interaction between subject groups and stimulus 
intensity. Post hoc analyses at each intensity showed a significant group effect only for 
the 0.2 and 0.3 msec stimuli. At those levels, the PMR-MTEP group was greater than 
both the control-untreated and the PMR-untreated groups.  In addition, the control-
MTEP group was also greater than the PMR-untreated group at both intensities and 
greater than the control-untreated group at 0.2 msec. 
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3.7 The effect of GBP treatment on SS-ChR IPSCs in control cortexTo determine 
if the second potential treatment, that with GBP had a direct effect on the SS-ChR 
IPSC, we compared the untreated controls to the GBP-treated controls (Figure 8). We 
again used a 2-way repeated measures ANOVA to test for significant differences (N = 
19 and 7 neurons for untreated and GBP). There was no significant effect of subject 
group and no significant interaction, but there was a significant effect of stimulus 
intensity (p<0.05). The same was true for measures of IPSC area and duration, where 
there was no significant difference between control-untreated and control-GBP and no 
significant interaction between stimulus intensity and subject group, but there was a 
significant effect of stimulus intensity. 
 
 
 
Figure 8. Does GBP affect the 
SS-ChR IPSC in control cortex? 
Untreated controls in black (N 
= 19) and GBP-treated controls 
in blue (N = 7). Measures of 
peak (A); area (B); and 
duration (C) of the IPSC are 
shown. A 2-way repeated 
measures ANOVA was used to 
test for significance. There was 
a significant effect of stimulus 
intensity only, for all three 
measures. 
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3.8 Does GBP prevent the PMR-associated increase in SS-ChR IPSC peak?  
To determine if GBP could prevent the PMR-associated increase in the peak of 
the IPSC evoked with optogenetic activation of SS interneurons, we first compared the 
results between control-GBP and PMR-GBP groups. Should MTEP be effective, it 
was expected that there would no longer be a significant difference between control 
and PMR when both were treated with GBP. That was in fact the case, based on a 2-
way ANOVA for just these groups (subject groups N.S. different, p>0.05). However it 
is possible that even without a significant difference that GBP was not returning the 
SS interneuron output to the normal (untreated control) levels.  
To examine this further, the results for four groups: untreated controls (19 
neurons), untreated PMR (14 neurons), control-GBP (7 neurons) and PMR-GBP (11 
neurons, see Figure 9) were compared. For IPSC peak, although there was a 
significant effect of subject group with the 2-way repeated measures ANOVA, there 
was a significant effect for stimulus intensity and also a significant interaction 
between stimulus intensity and subject group (p<0.05). Once there is an interaction, 
we have investigated this statistically, rather than examining the differences between 
subject groups. Post hoc analyses of the interaction were performed as described 
above, with 1-way ANOVAs at each intensity, with a Bonferroni correction applied to 
the p value. For peak IPSC, there was a significant group effect at stimulus intensities 
0.2, 0.3 and 0.4 msec. At these levels the PMR-GBP group was significantly larger 
than both control-untreated and PMR-untreated groups.  In addition, the control-GBP 
group was significantly larger than the PMR-untreated group at the 0.3 msec stimulus 
intensity. 
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For the area of the IPSC, there was an effect of stimulus intensity and an 
interaction between subject group and stimulus intensity. Post hoc analysis using 1-
way ANOVAs with Bonferroni correction applied to the p-value showed a significant 
effect of group for intensities 0..1, 0.2 and 0.3 msec. At these intensities, the PMR-
GBP group was significantly larger than control-untreated and PMR-untreated groups. 
In addition at the 0.2 msec level, the control-GBP group was significantly larger than 
PMR-untreated group. 
For the duration of the IPSC, the 2-way repeated measures ANOVA showed an 
effect of subject group, stimulus intensity and a significant interaction between these 
two. We again focused on the interaction to further understand these results. Post hoc 
analyses of 1-way ANOVAs at each stimulus intensity with Bonferroni correction 
applied to the p value, showed significant group effects at the 0.2, 0.3, and 0.4 msec 
levels. At these levels, the PMR-GBP group was significantly larger than both the 
control-untreated and the PMR-untreated groups.  In addition, at the 0.2 and 0.3 levels, 
the control-GBP was also significantly larger than both the control-untreated and 
PMR-untreated groups. It is however still clear that to draw firm conclusions, 
additional data will be necessary, given the large error bars and low power (see Table 
1) associated with the current data. 
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3.9 Is GBP more effective than MTEP in reducing the SS-ChR IPSC?  
While it is clear that for all four drug-treated groups additional neurons are 
needed to complete this project, here we attempted to compare the GBP and MTEP 
effects for this preliminary form of the data. To make direct comparisons of the effect 
of the drug on the PMR-associated changes, all PMR data was normalized to the mean 
of its respective control. For instance, each untreated PMR peak IPSC value was 
divided by the mean of the untreated control peak IPSC. This was repeated for MTEP 
and GBP groups. Thus for any given value if the PMR IPSC value was equal to that of 
the control, this procedure would yield a normalized value of 1. The results for the 
three measures of peak, area, and duration of the IPSC are shown in Figure 10. For 
Figure 9. Does GBP prevent 
the enhanced SS-ChR IPSC 
associated with the PMR? All 
features are the same as for 
figure 8, with the addition of 14 
PMR-untreated neurons and 11 
PMR-GBP neurons. There was 
a significant interaction 
between subject group and 
stimulus intensity on all 
measures (two-way repeated 
measures ANOVA, p<0.05.  See 
text and Table 1 for further 
effects. 
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the untreated group, the peak and the area of the IPSC was 3-4 times that of control on 
intensities of 0.5 msec and greater. In contrast, for both MTEP and GBP, the values 
were between 1 and 2 on the normalization scale, further demonstrating the lack of 
difference between control and PMR in the drug-treated groups. This figure shows that 
MTEP and GBP were not significantly different in their effectiveness. To test for 
significance, 2-way repeated measures ANOVAs were again used. The p values and 
observed power for this data is reported in Table 2. 
 
Figure 10. All PMR data 
normalized to their respective 
controls. MTEP and GBP are 
equally effective in reducing the 
enhanced SS-ChR IPSC in 
malformed brain. Measures of peak 
(A), area (B) and duration (C) 
shown. Untreated in green (N = 
14); MTEP in pink (N = 11); and 
GBP in blue (N=11). See Table 2 
for 2-way repeated measures 
ANOVA p values and observed 
power for the data shown here. 
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Table 1. p values and observed power in parentheses for all comparisons tested with a 
2-way repeated measures ANOVA shown in figures 6-9. Comparison groups are listed 
from left to right. IPSC measures of peak, area and duration are listed from top to 
bottom, respectively. Significant differences (p<0.05) shown in red. For these 
comparisons, N = 19 untreated control, 14 untreated PMR, 11 control-MTEP, 11 PMR-
MTEP, 7 control-GBP, and 11 PMR-GBP 
Table 2. p values and observed power in 
parentheses for the comparisons shown in Fig. 
10 and tested with 2-way repeated measures 
ANOVA. These data were normalized to the 
mean of their respective controls. IPSC measures 
of peak, area and duration are listed from top to 
bottom, respectively. Significant differences 
(p<0.05) shown in red. For these comparisons, N 
= 14 PMR-untreated, 11 PMR-MTEP, and 
11PMR-GBP neurons. 
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  Chapter 4 
Discussion 
 
Epilepsy has been previously attributed to increased excitation or decreased 
inhibition. With this frame of mind, modern medicine has been unable to develop an 
effective permanent treatment against the mechanisms of epilepsy for some patients. In 
order to treat patients with intractable seizures, especially those caused by developmental 
malformations, it is essential to understand the entirety of mechanisms that could 
possibly play a role in the abnormal cortical function. Excitatory afferents are increased 
in the PMR due to the presence of the microgyrus (Jacobs and Prince 2005). This 
suggests that the hyperexcitability is caused by these extra glutamatergic synapses; 
however, the early susceptibility to excitation does not coincide with the increased 
excitation onto pyramidal neurons and may actually be caused by changes in inhibitory 
interneurons (George and Jacobs 2006, George and Jacobs 2011, Bell and Jacobs 2014). 
This suggests a role for GABAergic interneurons in epileptogenesis. Previous studies 
have shown that excitation persists even with enhanced inhibitory function suggesting 
that the inhibition is not decreasing excitation in the network; blocking of the inhibition 
causes a decrease in epileptiform activity in some epilepsies or conditions (Mann and 
Mody 2008).  It was shown that in the PMR region, SS interneurons have an increased 
output compared to PV interneurons (George and Jacobs 2011). In addition, it has been 
shown that the mGluR5 receptor is enhanced in its presence in the PMR region in FL 
animals as opposed to control on these SS interneurons.  
The overall goal of this study was to determine if blockade of the mGluR5 receptor 
would inhibit the output from SS interneurons and therefore decrease the overall 
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excitation seen in the FL model. With the use of field potential recordings and 
optogenetics with patch clamping the following observations were made:  
Patch clamping was used to measure the output of the SS interneurons by selectively 
activating them with blue light using optogenetics. Field potential recordings were used 
in order to determine the presence of epileptiform activity in our experimental groups. 
MTEP was used on PMR and SHAM mice in order to reduce the output from the SS 
interneurons by blocking the mGluR5 receptor, and therefore, the overall 
hyperexcitability seen in the FL model. GBP was used as a drug control and was also 
used to treat PMR and SHAM mice. GBP blocks the interaction of TSP and the α2δ-1 
receptor and therefore inhibits excitatory synapse formation.  
There was epileptiform activity seen in all groups, even in untreated mice. It is 
normal, however, for untreated mice to have a certain amount of epileptiform activity due 
to high concentrations of NMDA receptors and not fully developed GABAergic systems 
(Luhmann and Prince 1990).  
In untreated PMR mice, the incidence of epileptiform activity is higher within the 
PMR than in homotopic control cortex. This is similar to what’s seen in the rat FL model. 
This increased amount of epileptiform activity in the PMR mice compared to controls 
suggests a developmental change.  
Results also showed a high rate of epileptiform activity in MTEP SHAM mice 
compared to untreated PMR mice. The incidence of epilepsy per slice in MTEP PMR 
mice was lower than MTEP SHAM mice. This suggests that MTEP decreases 
epileptiform activity, however, it also suggests that MTEP affects another aspect of the 
brain due to the high rate of epileptiform activity in the MTEP SHAM mice compared to 
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untreated PMR mice. The fact that epi incidence in slices from MTEP PMR mice was 
decreased– especially as compared to untreated PMR mice – suggests that MTEP may in 
fact be effective in reducing the malformation-associated causes of hyperexcitability.  
MTEP-treated controls did not differ from the untreated controls in peak, area, or 
duration of IPSCs at the longer light durations. The only difference was seen in the initial 
intensities (0.2, 0.3, 0.4 msec) for the IPSC duration. For MTEP PMR and control vs 
untreated PMR and control, there was a significant interaction between the groups at 
intensities 0.2, 0.3, and 0.4 msec light duration for the peak, at 0.2 msec in the IPSC area 
for MTEP PMR vs untreated groups and 0.2 and 0.3 msec for IPSC duration for MTEP 
PMR vs untreated groups. We currently do not know why there is increased SS 
interneuron output at these low intensities, however, future studies will look into this 
aspect. Some potential causes of the increased output could be technical error, possible 
biological differences in current mice, or a biological change due to MTEP in the cortex 
or elsewhere.  
An explanation for the amount of epileptiform activity is possibly due to MTEPs 
role in excitatory or inhibitory neuron formation. When mGluR5 is knocked out, cortical 
excitatory neurons receive reduced inhibitory inputs into layer IV, suggesting a role for 
mGlu5 in the functional development of GABAergic circuits (Ballester-Rosado, Albright 
et al. 2010). Additionally, mGluR5 plays an important role in radial-glial-mediated 
neuronal guidance which is important for normal neocortical function (Louhivuori, 
Jansson et al. 2014) so the blocking of this receptor could have detrimental effects. They 
showed that the interruption of the mGlu5 receptor hinders the activity of the canonical 
transient receptor potential (TRPC) channel family which has been shown to mediate the 
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responses of growth cones to guidance cues through their control of calcium currents. 
This in turn effects radial glial mediated neuronal guidance and may have an impact on 
specific neurons that are in the layers of the neocortex (Louhivuori, Jansson et al. 2014). 
This could affect the formation of the PMR because of the formation of the microgyrus 
and subsequent redirected afferents.   
 The mGluR5 receptor on SS interneurons was specifically targeted due to 
previous work demonstrating its enhanced presence in the PMR, but not in control. 
Previous studies in our lab have shown that these SS interneurons are more active in the 
PMR region and could be the cause of the hyperexcitability caused by the synchronous 
firing of pyramidal neurons due to SS interneuron synchronous inhibition.  
The fact that GBP-treated SHAM were similar to untreated controls in their epi 
incidence suggests that GBP has no effect on normal network excitability. GBP also 
appeared to have no effect on FL-induced hyperexcitability, since GBP PMR was similar 
to untreated PMR mice. This, however, is opposite of what was found in Andersen 
(2014). What could explain the difference in results could be the age that lesions were 
done as well as the severity of the lesion. We do a bilateral lesion as compared to a 
unilateral lesion and our mice had the FL at age P1 instead of P0. Andersen (2014) found 
no difference in the amount of epileptiform activity in GBP treated FL animals compared 
to SHAM injured animals (Andresen, Hampton et al. 2014), concluding that GBP was 
able to reduce in vitro cortical hyperexcitability after an induced FL.    
The effects of GBP treatment showed significant effects at low intensities of IPSC 
peak, duration, and area in the GBP PMR group compared to the untreated groups. 
Again, it is not known why there is increased SS interneuron output at these low 
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intensities, however, future studies will look into this aspect. Additionally, there was no 
difference seen in the SS interneuron output in GBP PMR or GBP SHAM groups when 
compared.  
Translation and relevance of project:  
Current AEDs cause either a decrease in excitation, like GBP, or cause an increase in 
inhibition. Most AEDs work fairly well, but not all seizures are treatable with these 
AEDs. The alternative when AEDs do not work is invasive surgery. AEDs also generally 
have problems such as problematic drug interaction and other aversive side effects and do 
not work well in patients with PMG. Targeting the mGluR5 receptor is attractive due to 
the fact that this receptor is not normally expressed in high amounts in normal control 
tissue. Because of this, MTEP, an mGluR5 receptor antagonist, may not cause the 
extensive side effects as other AEDs. MTEP blockade of the mGlu5 receptor shows 
promise in its ability to decrease SS interneuron output, however, further experimentation 
is needed. This type of mechanism, if translatable to humans, could result in a successful 
treatment for previously intractable epilepsies associated with developmental 
malformations.  
These experiments showed that there is a possible role of the mGluR5 in the decrease 
in epileptiform activity caused by developmental malformations, however, additional 
drug experiments need to be done to determine MTEP’s efficiency in aiding in this 
process.  
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Further directions: 
Further investigation into the mechanisms of SS interneuron maturation will help 
further narrow down the areas to which treatments can be applied. One possibility is 
different maturation times. Knowing the mechanisms of SS interneuron maturation would 
be a helpful study in order to determine why they have increased expression of mGluR5.  
Further studies involving the drug, rapamycin, an mTOR pathway inhibitor, would be 
a promising next step. The mTOR pathway is one of many pathways activated by the 
mGlu5 receptor. MTOR is a rapamycin-sensitive serine-threonine kinase that plays a role 
in mRNA translation initiation, consequently affecting cell growth, dendritic arborization, 
neuronal morphology, proliferation, and cortical development (Meyuhas 2000, Chen, 
Atkins et al. 2007, Nguyen, Brewster et al. 2015). Due to MCDs being linked to problems 
in genes encoding known regulators of the mTOR pathway, blocking this pathway seems 
to be a logical step in potential treatments (Nguyen, Brewster et al. 2015). Because 
mGluR5 has been shown to be important in development, narrowing down treatment to a 
specific pathway activated by this receptor might be the key to a potential therapeutic 
treatment for intractable epilepsies in order for the partial function of this receptor to 
remain intact. Additionally, mTOR is a promising next step because some studies have 
shown that in seizures that are difficult to treat, MTEP’s use to block the mGlu5 receptor 
is ineffective (Witkin, Baez et al. 2008).  
There are many future directions to be taken in order to elucidate the role of mGluR5 
in the increased output from SS interneurons. Due to the complexity of the cascading 
pathways activated by this receptor, there needs to be further experimentation in order to 
determine a specific mechanism to control these SS interneurons.  
62 
 
References 
 
Alexander, G. M. and D. W. Godwin (2006). "Metabotropic glutamate receptors as a 
strategic target for the treatment of epilepsy." Epilepsy Res. 71(1): 1-22. 
Andresen, L., D. Hampton, A. Taylor-Weiner, L. Morel, Y. Yang, J. Maguire and C. G. 
Dulla (2014). "Gabapentin attenuates hyperexcitability in the freeze-lesion model of 
developmental cortical malformation." Neurobiol Dis 71: 305-316. 
Arikkath, J. and K. Campbell (2003). "Auxiliary subunits: essential components of the 
voltage-gated calcium channel complex." Current Opinion in Neurobiology 13(3): 298-
307. 
Ballester-Rosado, C. J., M. J. Albright, C. S. Wu, C. C. Liao, J. Zhu, J. Xu, L. J. Lee and 
H. C. Lu (2010). "mGluR5 in cortical excitatory neurons exerts both cell-autonomous and 
-nonautonomous influences on cortical somatosensory circuit formation." J Neurosci 
30(50): 16896-16909. 
Barkovich, A. J., R. Guerrini, R. I. Kuzniecky, G. D. Jackson and W. B. Dobyns (2012). 
"A developmental and genetic classification for malformations of cortical development: 
update 2012." Brain 135(Pt 5): 1348-1369. 
Bell, A. and K. M. Jacobs (2014). "Early susceptibility for epileptiform activity in 
malformed cortex." Epilepsy Res 108(2): 241-250. 
Ben Ari, Y. (2006). "Basic developmental rules and their implications for epilepsy in the 
immature brain." Epileptic.Disord. 8(2): 91-102. 
Buckmaster, P. S. and F. E. Dudek (1997). "Neuron loss, granule cell axon 
reorganization, and functional changes in the dentate gyrus of epileptic kainate-treated 
rats." J.Comp Neurol. 385(3): 385-404. 
Chen, S., C. Atkins, C. Liu, O. Alonso, W. Dietrich and B. Hu (2007). "Alterations in 
mammalian target of rapamycin signaling pathways after traumatic brain injury." Journal 
of Cerebral Blood Flow & Metabolism 27: 939-949. 
Colmers, W., K. Lukowiak and Q. Pittman (1987). "Presynaptic action of neuropeptide Y 
in area CA1 of the rat hippocampal slice." J Physiol 383: 285-299. 
63 
 
Connors, B. W. and M. J. Gutnick (1990). "Intrinsic firing patterns of diverse neocortical 
neurons." Trends Neurosci. 13: 99-104. 
Cosford, N., L. Tehrani, J. Roppe, E. Schweiger, N. Smith, J. Anderson and L. Bristow 
(2003). "3-[(2-Methyl-1, 3- thiazol-4-yl)-pyridine: a potent and highly selective 
metabotropic glutamate subtype 5 receptor antagonist with anxiolytic activity." J Med 
Chem 46: 204-206. 
Davies, J. A. (1995). "Mechanisms of action of antiepileptic drugs." Seizure 4: 267-272. 
De Ciantis, A., A. J. Barkovich, M. Cosottini, C. Barba, D. Montanaro, M. Costagli, M. 
Tosetti, L. Biagi, W. B. Dobyns and R. Guerrini (2015). "Ultra-High-Field MR Imaging 
in Polymicrogyria and Epilepsy." AJNR Am J Neuroradiol 36(2): 309-316. 
DeFelipe, J., S. R. Garcia, P. Marco, R. M. del, P. Pulido and Ramon (1993). "Selective 
changes in the microorganization of the human epileptogenic neocortex revealed by 
parvalbumin immunoreactivity." Cereb.Cortex 3: 39-48. 
Deisseroth, K. (2011). "Optogenetics." Nature Methods 8: 26-29. 
Demeulemeester, H., F. Vandesande, G. A. Orban, C. Brandon and J. J. Vanderhaeghen 
(1988). "Heterogeneity of GABAergic cells in cat visual cortex." J.Neurosci. 8: 988-
1000. 
Domin, H., M. Kajta and M. Smialowska (2006). "Neuroprotective effects of MTEP, a 
selective mGluR5 antagonists and neuropeptide Y on the kainate-induced toxicity in 
primary neuronal cultures." Pharmacol.Rep. 58(6): 846-858. 
Elger, C. E. (2005). "Epilepsy: a model for the study of brain function." Lancet Neurol. 
4(1): 3. 
Eroglu, C., N. Allen, M. Susman, N. O'Rourke, C. Park, E. Ozkan, C. Chakraborty, S. 
Mulinyawe, D. Annis, A. Huberman, E. Green, J. Lawler, R. Dolmetsch, K. Garcia, S. 
Smith, Z. Luo, A. Rosenthal, D. Mosher and B. Barres (2009). "Gabapentin receptor 
alpha2delta-1 is a neuronal thrombospondin receptor responsible for excitatory CNS 
synaptogenesis." Cell 139(2): 380-392. 
Fenno, L., O. Yizhar and K. Deisseroth (2011). "The Development and Application of 
Optogenetics." Annual Review of Neuroscience, Vol 34 34: 389-412. 
64 
 
Fisher, R. and M. Saul (1997). Overview of Epilepsy: 35. 
Fisher, R. A., C, A. Arzimanoglou, A. Bogacz, J. Cross, C. Elger, J. Engel Jr, L. 
Forsgren, J. French, M. Glynn, D. Hesdorffer, B. Lee, G. Mathern, S. Moshe, E. Perucca, 
I. Scheffer, T. Tomson, M. Watanabe and S. Wiebe (2014). "A practical clinical 
definition of epilepsy." Epilepsia 55(4): 475-482. 
Galarreta, M. and S. Hestrin (1998). "Frequency-dependent synaptic depression and the 
balance of excitation and inhibition in the neocortex." Nat.Neurosci 1(7): 587-594. 
Gasparini, F., K. Lingenhohl, N. Stoehr, P. J. Flor, M. Heinrich, I. Vranesic, M. Biollaz, 
H. Allgeier, R. Heckendorn, S. Urwyler, M. A. Varney, E. C. Johnson, S. D. Hess, S. P. 
Rao, A. I. Sacaan, E. M. Santori, G. Velicelebi and R. Kuhn (1999). "2-Methyl-6-
(phenylethynyl)-pyridine (MPEP), a potent, selective and systemically active mGlu5 
receptor antagonist." Neuropharmacology 38(10): 1493-1503. 
George, A. L. and K. M. Jacobs (2006). "Excitatory synaptic input to interneuron 
subpopulations is modified in malformed cortex." Society for Neuroscience Abstracts 32: 
278. 
George, A. L. and K. M. Jacobs (2011). "Altered intrinsic properties of neuronal subtypes 
in malformed epileptogenic cortex." Brain Res 1374: 116-128. 
Gibson, J. R., M. Beierlein and B. W. Connors (1999). "Two networks of electrically 
coupled inhibitory neurons in neocortex." Nature 402: 75-79. 
Gonzales-Burgos, G., L. S. Krimer, N. V. Povysheva, G. Barrionuevo and D. A. Lewis 
(2005). "Functional Properties of Fast Spiking Interneurons and Their Synaptic 
Connections With Pyramidal Cells in Primate Dorsolateral Prefrontal Cortex." Journal of 
Neurophysiology 93(2): 942-953. 
Hannan, A. J., C. Blakemore, T. Vitalis, K. M. Huber, M. Bear, J. Roder, D. Kim, H. S. 
Shin and P. C. Kind (2001). "Phospholipase C-β1, activated via mGluRs, mediates 
activity-dependent differentiation in cerebral cortex." Nat Neurosci 4: 282-288. 
Hendrich, J., A. Tran Van Minh, F. Heblich, M. Nieto-Rostro, K. Watschinger, J. 
Striessnig, J. Wratten, A. Davies and A. Dolphin (2008). "Pharmacological disruption of 
calcium channel trafficking by the α2δ ligand gabapentin." Proc Natl Acad Sci U S A 
105(9): 3628-3633. 
65 
 
Hu, H., J. Z. Cavendish and A. Agmon (2013). "Not all that glitters is gold: off-target 
recombination in the somatostatin-IRES-Cre mouse line labels a subset of fast-spiking 
interneurons." Front Neural Circuits 7: 195. 
Hu, H., J. Gan and P. Jonas (2014). "Interneurons. Fast-spiking, parvalbumin(+) 
GABAergic interneurons: from cellular design to microcircuit function." Science 
345(6196): 529-542. 
Humphreys, P., G. D. Rosen, D. M. Press, G. F. Sherman and A. M. Galaburda (1991). 
"Freezing lesions of the developing rat brain: A model for cerebrocortical microgyria." 
J.Neuropathol.Exp.Neurol. 50: 145-160. 
Jacobs, K. M., B. J. Hwang and D. A. Prince (1999). "Focal epileptogenesis in a rat 
model of polymicrogyria." Journal of Neurophysiology 81: 159-173. 
Jacobs, K. M., V. N. Kharazia and D. A. Prince (1999). "Mechanisms underlying 
epileptogenesis in cortical malformations." Epilepsy Research 36: 165-188. 
Jacobs, K. M. and D. A. Prince (2005). "Excitatory and inhibitory postsynaptic currents 
in a rat model of epileptogenic microgyria." J Neurophysiol. 93(2): 687-696. 
Jong, Y. J., I. Sergin, C. A. Purgert and K. L. O'Malley (2014). "Location-dependent 
signaling of the group 1 metabotropic glutamate receptor mGlu5." Mol Pharmacol 86(6): 
774-785. 
Kawaguchi, Y. and Y. Kubota (1995). Local circuit neurons in the frontal cortex and the 
neostriatum. Functions of cortico-basal ganglia loop M. Kimura and A. Graybiel. Tokyo, 
Springer: 73-88. 
Kawaguchi, Y. and Y. Kubota (1996). "Physiological and morphological identification of 
somatostatin- or vasoactive intestinal polypeptide-containing cells among GABAergic 
cell subtypes in rat frontal cortex." J Neurosci. 16(8): 2701-2715. 
Kim, Y.-S., H.-K. Chang, J.-W. Lee and C.-J. Kim (2009). "Protective Effect of 
Gabapentin on N-Methyl-D-aspartate–Induced Excitotoxicity in Rat Hippocampal CA1 
Neurons." Journal of Pharmocological Sciences 109(1): 144-147. 
Konig, P., A. Engel and W. Singer (1996). "Integrator or coincidence detector? The role 
of the cortical neuron revisited." Trends Neurosci. 19: 130-137. 
66 
 
Kubota, Y., R. Hattori and Y. Yui (1994). "Three distinct subpopulations of GABAergic 
neurons in rat frontal agranular cortex." Brain Res. 649: 159-173. 
Kuzniecky, R. (2015). "Epilepsy and malformations of cortical 
development: new developments." Current Opinion: 151-157. 
Kuzniecky, R., F. Andermann and R. Guerrini (1993). "Congenital bilateral perisylvian 
syndrome: study of 31 patients. The CBPS Multicenter Collaborative Study." Lancet 341: 
608-612. 
LaLumiere, R. T. (2011). "A new technique for controlling the brain: optogenetics and its 
potential for use in research and the clinic." Brain Stimul 4(1): 1-6. 
Lea, P. M. and A. I. Faden (2006). "Metabotropic glutamate receptor subtype 5 
antagonists MPEP and MTEP." CNS.Drug Rev. 12(2): 149-166. 
Lea, P. M., V. A. Movsesyan and A. I. Faden (2005). "Neuroprotective activity of the 
mGluR5 antagonists MPEP and MTEP against acute excitotoxicity differs and does not 
reflect actions at mGluR5 receptors." Br.J.Pharmacol. 145(4): 527-534. 
Levenga, J., F. M. S. de Vrij, B. Oostra and R. Willemsen (2010). "Potential therapeutic 
interventions for fragile X syndrome." Trends in Molecular Medicine 16(11): 516-527. 
Leventer, R. J., R. Guerrini and W. B. Dobyns (2008). "Malformations of cortical 
development and epilepsy." Dialogues.Clin.Neurosci. 10(1): 47-62. 
Loscher, W., A. Dekundy, J. Nagel, W. Danysz, C. G. Parsons and H. Potschka (2006). 
"mGlu1 and mGlu5 receptor antagonists lack anticonvulsant efficacy in rodent models of 
difficult-to-treat partial epilepsy." Neuropharmacology 50(8): 1006-1015. 
Louhivuori, L. M., L. Jansson, P. M. Turunen, M. H. Jantti, T. Nordstrom, V. Louhivuori 
and K. E. Akerman (2014). "Transient Receptor Potential Channels and Their Role in 
Modulating Radial Glial-Neuronal Interaction: A Signaling Pathway Involving mGluR5." 
Stem Cells Dev. 
Luhmann, H. J. and D. A. Prince (1990). "Transient expression of polysynaptic NMDA 
receptor-mediated activity during neocortical development." Neurosci Lett 111(1-2): 109-
115. 
67 
 
Lujan, R., R. Shigemoto and G. Lopez-Bendito (2005). "Glutamate and GABA receptor 
signalling in the developing brain." Neuroscience 130(3): 567-580. 
Luttrell, L. and R. Lefkowitz (2002). "The role of β-arrestins in the termination and 
transduction of G-protein-coupled receptor signals." Journal of Cell Science 155: 455-
465. 
Mann, E. O. and I. Mody (2008). "The multifaceted role of inhibition in epilepsy: 
seizure-genesis through excessive GABAergic inhibition in autosomal dominant 
nocturnal frontal lobe epilepsy." Curr.Opin.Neurol. 21(2): 155-160. 
Markram, H., M. Toledo-Rodriguez, Y. Wang, A. Gupta, G. Silberberg and C. Wu 
(2004). "Interneurons of the neocortical inhibitory system." Nat.Rev.Neurosci. 5(10): 
793-807. 
Martin, D. J., D. McClelland, M. B. Herd, K. G. Sutton, M. D. Hall, K. Lee, R. D. 
Pinnock and R. H. Scott (2002). "Gabapentin-mediated inhibition of voltage-activated 
Ca2+ channel currents in cultured sensory neurones is dependent on culture conditions 
and channel subunit expression." Neuropharmacology 42(3): 353-366. 
Meyuhas, O. (2000). "Synthesis of translational apparatus is regulated at the trasnlational 
level." Eur J Biochem 267: 6321-6330. 
Nagal, J., S. Greco, C. Parsons, G. Flik, C. Tober, K. Klein and W. Danysz (2015). 
"Brain concentrations of mGluR5 negative allosteric modulator MTEP in relation to 
receptor occupancy – Comparison to MPEP." Pharmacological Reports 67(3): 624-630. 
Nguyen, L., A. Brewster, M. Clark, A. Regnier-Golanov, N. Sunnen, V. Patil, G. 
D'Arcangelo and A. Anderson (2015). "mTOR inhibition suppresses established epilepsy 
in a mouse model of cortical dysplasia." Epilepsia: 1-11. 
Olive, M. F., A. J. McGeehan, J. R. Kinder, T. McMahon, C. W. Hodge, P. H. Janak and 
R. O. Messing (2005). "The mGluR5 antagonist 6-methyl-2-(phenylethynyl)pyridine 
decreases ethanol consumption via a protein kinase C epsilon-dependent mechanism." 
Mol.Pharmacol. 67(2): 349-355. 
Olivier, A., F. Andermann, A. Palmini and Y. Robitaille (1996). Surgical treatment of the 
cortical dysplasias. Dysplasias of Cerebral Cortex and Epilepsy. R. Guerrini, F. 
Andermann, R. Canapicchi et al. Philadelphia, Lippincott-Raven Publishers: 351-366. 
68 
 
Palmini, A., A. Gambardella, F. Andermann, F. Dubeau, C. J. Da, A. Olivier, D. 
Tampieri, Y. Robitaille, E. Paglioli and N. E. Paglioli (1994). "Operative strategies for 
patients with cortical dysplastic lesions and intractable epilepsy." Epilepsia 35 Suppl 6: 
S57-S71. 
Petersen, C. C. H. (2007). "The Functional Organization of the Barrel Cortex." Neuron 
56(2): 339-355. 
Powell, E. M., D. B. Campbell, G. D. Stanwood, C. Davis, J. L. Noebels and P. Levitt 
(2003). "Genetic disruption of cortical interneuron development causes region- and 
GABA cell type-specific deficits, epilepsy, and behavioral dysfunction." J Neurosci. 
23(2): 622-631. 
Rakhade, S. N. and F. E. Jensen (2009). "Epileptogenesis in the immature 
brain: emerging mechanisms." Nat. Rev. Neurol. 5: 380-391. 
Rogers, J. (1992). "Immunohistochemical markers in rat cortex: colocalization of 
calretinin and calbindin-D28k with neuropeptides and GABA." BRain Res 587: 147-157. 
Rosen, G. D., D. Burstein and A. M. Galaburda (2000). "Changes in efferent and afferent 
connectivity in rats with induced cerebrocortical microgyria." J Comp Neurol 418: 423-
440. 
Rosen, G. D., K. M. Jacobs and D. A. Prince (1998). "Effects of neonatal freeze lesions 
on expression of parvalbumin in rat neocortex." Cereb.Cortex 8(8): 753-761. 
Rosenbaum, D., S. Rasmussen and B. Koblika (2009). "The structure and function of G-
protein-coupled receptors." Nature 459: 356-363. 
Slassi, A., M. Isaac, L. Edwards, A. Minidis, D. Wensbo, J. Mattsson, K. Nilsson, P. 
Raboisson, D. McLeod, T. M. Stormann, L. G. Hammerland and E. Johnson (2005). 
"Recent advances in non-competitive mGlu5 receptor antagonists and their potential 
therapeutic applications." Curr.Top.Med.Chem. 5(9): 897-911. 
Squier, W. and A. Jansen (2010). "Abnormal development of the human cerebral cortex." 
J Anat 217(4): 312-323. 
Stouffer, M., J. Golden and F. Francis (2015). "Neuronal migration disorders: Focus on 
the cytoskeleton and epilepsy." Neurobiology of Disease: 1-28. 
69 
 
Szydlowska, K., B. Kaminska, A. Baude, C. G. Parsons and W. Danysz (2007). 
"Neuroprotective activity of selective mGlu1 and mGlu5 antagonists in vitro and in 
vivo." Eur.J.Pharmacol. 554(1): 18-29. 
Takano, T. (2011). "Seizure susceptibility in polymicrogyria: clinical and experimental 
approaches." Epilepsy Res 96(1-2): 1-10. 
Traa, B., J. Mulholland, S. Kadam, M. Johnston and A. Comi (2008 ). "Gabapentin 
neuroprotection and seizure suppression in immature mouse brain ischemia." Pediatric 
Research 64(1): 81-85. 
Trotter, S. A., J. Kapur, M. J. Anzivino and K. S. Lee (2006). "GABAergic synaptic 
inhibition is reduced before seizure onset in a genetic model of cortical malformation." 
J.Neurosci. 26(42): 10756-10767. 
Varvel, N. H., J. Jiang and R. Dingledine (2014). "Candidate drug targets for prevention 
or modification of epilepsy." Annu Rev Pharmacol Toxicol 55: 229-247. 
Wang, T., T. Kumada, T. Morishima, S. Iwata, T. Kaneko, Y. Yanagawa, S. Yoshida and 
A. Fukuda (2012). "Accumulation of GABAergic Neurons, Causing a Focal Ambient 
GABA Gradient, and Downregulation of KCC2 Are Induced During Microgyrus 
Formation in a Mouse Model of Polymicrogyria." Cereb.Cortex. 
Wang, Y., A. Gupta, M. Toledo-Rodriguez, C. Z. Wu and H. Markram (2002). 
"Anatomical, physiological, molecular and circuit properties of nest basket cells in the 
developing somatosensory cortex." Cereb Cortex 12(4): 395-410. 
White, E. L. (1989). Cortical Circuits. Synaptic Organization of the Cerebral Cortex, 
Birkhäuser Basel. 
WHO, I. L. A. Epilepsy and I. B. f. Epilepsy (2005). Atlas: Epilepsy Care in the World 
2005. 
Witkin, J., M. Baez, J. TYu and W. Eiler (2008). "mGlu5 receptor deletion does not 
confer seizure protection to mice." Life Sci. 83: 377-380. 
Wong, R. K., R. Bianchi, S. C. Chuang and L. R. Merlin (2005). "Group I mGluR-
induced epileptogenesis: distinct and overlapping roles of mGluR1 and mGluR5 and 
implications for antiepileptic drug design." Epilepsy Curr. 5(2): 63-68. 
70 
 
Woolsey, T. A. and H. van der Loos (1970). "The structural organization of layer IV in 
the somatosensory region (SI) of mouse cerebral cortex. The description of a cortical 
field composed of discrete cytoarchitectonic units." Brain Res. 17: 205-242. 
Zhou, F. M. and J. J. Hablitz (1997). "Metabotropic glutamate receptor enhancement of 
spontaneous IPSCs in neocortical interneurons." Journal of Neurophysiology 78(5): 
2287-2295. 
 
